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Abstract 
This thesis addresses three primary questions based on the pharmacodynamics (PD) or 
pharmacokinetics (PK) of the diabetes drug exendin 4 (Ex-4), and vitamin B12 (B12) bioconjugates, 
thereof.  
Q1. (Chapter 2) What effect does B12 conjugation to Ex-4 have on agonism of the glucagon-like peptide-1 
receptor (GLP-1R) in vitro and on PD/PK (including brain uptake and function) in vivo? 
Goal: To remove side-effects (nausea, weight loss) of Ex-4 without loss of glucoregulation. 
Q2. (Chapter 3) Can B12 dietary uptake proteins such as gastric intrinsic factor offer protection to B12 
conjugated peptides or proteins (focusing on Ex-4), with a view to improving in vivo PK? 
Goal: To demonstrate (in vivo) that IF binding of B12-Ex-4 confers protection against gastric 
proteolysis as a road-map to oral peptide delivery. 
Q3. (Chapter 4) Can a dual agonist of the GLP-1R and neuropeptide Y2 receptor, based on the Ex-4 
primary amino acid sequence, be designed and validated in vitro and in vivo. 
Goal: To create a new therapeutic to simultaneously treat diabetes and obesity. 
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Chapter 1: Introduction 
1.1 Vitamin B12 (B12) 
Vitamin B12 (B12) is one of thirteen essential vitamins and the most recently discovered (see Figure 1).1 B12 
is a deep red color and has been referred to as “nature’s most beautiful cofactor”.2 B12 is in a rare category 
as a naturally occurring organometallic and was the first such compound discovered.3,4 Humans cannot 
produce B12, as it is made only by certain prokaryotes such as Pseudomonas denitrificans, and so we must 
acquire it entirely through diet.5,6,7,8,9,10 B12 is a water soluble molecule and readily degraded in the 
presence of acid.11 Humans employ a complex system of binding proteins and receptors in order to 
navigate the human gastrointestinal tract (GIT) and deliver B12 into the blood stream, then proliferating 
cells, including those in the brain.  A typical human takes in 1 -5 µg per day of B12 but the body can store 
B12 in the liver for up to five years and a deficiency can take years to discover.12 Deficiency is typically the 
result of a defect relating to the production of binding proteins such as intrinsic factor (IF). There are no 
known cases of overdosing from B12 and no recommended upper limit in dosage.13  
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Figure 1. B12 (cobalamin) structure, shown as cyanocobalamin. 
 The core of B12, also known as cobalamin, is comprised of a corrin ring chelating a cobalt(III) ion. 
This corrin ring, which is responsible for the red color of B12, has two sides, α and β (see Figure 1). The 
corrin ring is similar to a porphyrin ring with key differences being the lower saturation in the corrin (3/4 
vs 4/4) and the greater asymmetry of the corrin due to the loss of a methylene bridge between pyrrole 
rings C and D (also resulting in one less carbon (19) compared to the porphyrin (20)).14 On the α- side there 
is a 5,6-dimethylbenzimidazole (DMB) coordinated to the cobalt ion through a nitrogen atom. Off this 
DMB is a ribose moiety connected to the corrin ring through a phosphate and amide linker.  Although 
there are several functional groups located on B12, conjugations, made at the 5’-hydroxyl of the ribose 
moiety, maintain the most significant binding affinity by B12 binding proteins.15,16 
1.1.1 History of B12: Discovery and Diseases 
Symptoms of pernicious anemia, a disease characterized by pallor, sharp pains and excessive 
urination, were first described by physicians in the 1800s.17,18 Significant progress toward a cure for the 
disease, which was typically fatal at the time, did not come until the 1900s. The first major breakthrough 
was published in 1925 when Whipple, through research on anemia induced by blood loss in dogs, 
discovered that a diet composed of liver, particularly raw bovine liver, helped the dogs recover.19,20 This 
led to the first idea of B12, which was that there had to be something present in liver that was promoting 
recovery in pernicious anemia. Minot and Murphy then showed in 1926 that 45 patients with pernicious 
anemia given a daily meal consisting of bovine liver for several months, significantly improved.21 The 
discovery of effective pernicious anemia treatment won Minot, Murphy and Whipple the Nobel prize in 
chemistry in 1934.22  
Castle set out to address why liver was effective in treating pernicious anemia. His discoveries, 
through a set of experiments published in 1929 and 1930 using gastric juices from patients with and 
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without pernicious anemia, led him to believe that the meat had some factor that could only be utilized 
if those juices were present.23,24 What Castle realized was that, although the treatment to pernicious 
anemia was extrinsic factor (B12) and the cause was B12 deficiency, the real problem was a lack of IF, which 
rendered the body unable to access B12.  
The compound responsible for the Nobel prize in 1934 wasn’t isolated until over a decade later.25 
In 1947, B12 was simultaneously crystallized by Folkers at Merck and Smith at Glaxo and published in 
Nature and Science, respectively.26,27 The second Nobel prize for B12 was awarded in 1964 to Dorothy 
Hodgkin for determining the single-crystal X-ray structure of B12 in 1955.28   
1.1.2 Metabolism of B12 
B12 acts as a cofactor in two enzymatic processes (see Figure 2). The first, with cytosolic 
methionine synthase, is the conversion of homocysteine to methionine, and the second, with 
mitochondrial methylmalonyl coenzyme A (COA) mutase, is the conversion of methylmalonyl-COA to 
succinyl-COA.  
 
Figure 2. Representation of B12 coenzyme function in methionine synthase and methylmalonyl-COA 
synthase.  
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As the coenzyme for methionine synthase, a methyl group is transferred to homocysteine from 
5-methyl-tetrahydrofolate (5-methyl-THF) producing methionine and THF.  During this transfer B12 plays 
a role in remethylating homocysteine and accepting a methyl group from 5-methyl-THF. In the absence of 
B12, 5-methyl-THF is not converted to THF, which is necessary for DNA synthesis, and homocysteine 
accumulates causing cellular stress.29 B12 is also essential for the conversion of methylmalonyl-CoA mutase 
to succinyl CoA.30 During this conversion adenosylcobalamin is the coenzyme to methylmalonyl-CoA 
mutase in the conversion of methylmalonyl-CoA to succinyl-CoA.  
1.1.3 Dietary uptake of B12 in humans 
Humans have a complicated uptake system for B12 requiring specific transport proteins to get B12 
from dietary sources to proliferating cells. The uptake pathway of B12 is designed to both protect and 
transport. The first two proteins [haptocorrin (HC) and IF] transport B12 from the food into the blood and 
the last protein directs B12 to proliferating cells. Figure 3 shows the dietary uptake pathway of B12 and how 
each transport protein is utilized to bring B12 from the diet to the cell.  
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Figure 3. B12 dietary uptake pathway. HC: Haptocorrin; MRP: Multidrug resistant protein 1; IF: Intrinsic 
factor; TCII: Transcobalamin II; CD320: Cluster of differentiation 320. 
1.1.4 Transport proteins Involved in B12 dietary uptake 
There are three binding proteins for the dietary uptake of B12. The binding proteins ensure that 
B12 makes it from food to the cells. These proteins begin chaperoning B12 as soon as the food starts to be 
broken down in the mouth. Protection is necessary since B12 is unstable in the low pH environment of the 
stomach and, hence prone to degradation (much like a peptide would be).   
1.1.4.1 Haptocorrin (HC) 
The first binding protein involved in B12 trafficking is HC, alternative names for which are 
transcobalamin I or R-binder. HC is the least specific of B12’s binding proteins and recognizes partially 
degraded fragments of B12 along with intact B12 with picomolar affinity.31 HC is a heavily glycosylated ~65 
kDa protein and found in both the saliva and blood stream.32 Figure 3 shows the crystal structure of holo-
HC.33 The HC protein encapsulates B12 protecting it from degradation in the stomach. B12 is then carried 
into the duodenum, where the HC is degraded by pancreatic proteases and the B12 is picked up by IF.34  
5
 Figure 4. Structure of Holo-HC (pdb: 4KKI), showing the hetero-dimeric nature of the protein with the B12 
bound at the interface of the dimer. 
1.1.4.2 Intrinsic Factor (IF) 
The second carrier protein responsible for transporting B12 through the intestinal tract and into 
the blood is IF, a 50 kDa glycoprotein. The crystal structure of IF, shown in Figure 5 as an IF-B12 complex, 
reveals that it is structurally very similar to HC, being composed of two separate domains and binding B12 
between these domains.35 IF, unlike HC, is resistant to pancreatic proteases and binds B12 in the duodenum 
with picomolar affinity.34 IF-B12 travels through the intestines and is bound by the cubilin-amnionless 
(cubam) receptor in the terminal ileum and internalized into the ileal enterocyte.36  Cathepsin L is 
responsible for the breakdown of IF in the lysosome and subsequent release of B12.37  
A lack of IF causes most B12 deficiencies and is particularly known as the cause of pernicious 
anemia.17 Pernicious anemia is an autoimmune disorder that results in the loss of the gastric parietal cells 
responsible for producing IF. This disease is progressive and was considered fatal in the 1800s, since it led 
to an eventual clinical deficiency of B12. Research into a cure for this disease drove the discovery of B12.18 
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Figure 5. Structure of Holo-IF (pdb: 2PMV), showing the hetero-dimeric nature of the protein with the B12 
bound at the interface of the dimer. 
1.1.4.3 Transcobalamin (TCII) 
TCII (shown in Figure 6), the final B12 transport protein, is responsible for the delivery of B12 to the 
cells.38 The TCII-B12 complex is delivered to the cells through the CD320 receptor.39 Unsaturated TCII is 
found in blood at a concentration of 0.6-1.5 nM in humans, 2 nM in rats, and 20 nM in mice.40 It is 
important to consider that rat and mouse models differ in apo-TCII concentration. The TCII concentration 
is of particular importance when considering B12 conjugation as a method to deliver peptides orally. This 
is because the concentration of B12 will have to be over the TCII concentration, or the conjugate may be 
lost to B12 uptake into proliferating cells.   
7
 Figure 6. Structure of Holo-TCII (pdb: 2BB5), showing the hetero-dimeric nature of the protein with the 
B12 bound at the interface of the dimer. 
1.1.5 Drug development using B12 and its dietary pathway 
B12 and its dietary uptake pathway offer considerable potential in drug development.41 The first 
research avenue to be explored was oral delivery of peptides or proteins.42,43 The hypothesis was that the 
binding proteins that protect and transfer B12 could be manipulated to provide the same protection to 
peptides and proteins. Another area for research involves the brain uptake of B12. The hydrophilic nature 
of B12 requires a receptor mediated transfer across the blood brain barrier (BBB). The transfer is done 
through the CD320 receptor and only transports B12 in the form of a TCII-B12.  
One concern involved with B12 conjugation work is the potential for B12 to simply act as B12. Will a B12 
compound act like B12 or the drug upon delivery? When B12 is in the blood TCII will bind it and deliver it to 
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proliferating cells so administration over the TCII binding capacity should allow the B12 conjugate to 
behave like the peptide. The second question is whether a B12 conjugation will interfere with the function 
of the drug or molecule. If conjugation cannot be done in a way to maintain function the complex will not 
work. The obstacles are not unique to B12 and can be mitigated with proper controls and dosing.   
1.2 Diabetes Mellitus 
Diabetes Mellitus is a disease that affects just under 30 million Americans. There are two types of 
diabetes mellitus, type 1 (T1DM) and type 2 (T2DM).44 T1DM is an autoimmune disease which destroys 
the insulin producing beta cells and is typically diagnosed before the age of 30.45 Since there are no beta 
cells and insulin cannot be produced the most effective form of treatment is insulin injections. T2DM is 
caused by a resistance to insulin.46,47 The β-cells are present and producing insulin in T2DM patients but 
the body isn’t properly utilizing it to clear the glucose from the blood into the cells.48   
Insulin and glucagon are used in the body to directly control glucose levels. A change in normal glucose 
levels can be very dangerous to the body so insulin and glucagon work to maintain an homeostasis. Insulin 
is responsible for glucose entering the cell and glucagon is responsible for the release of glucose stores 
into the blood.49 Both hypoglycemia and hyperglycemia can cause serious health issues and death if not 
properly treated.50,51  
Insulin is regulated through glucose stimulated insulin secretion (GSIS). An increase in blood glucose 
levels, causing hyperglycemia, triggers K+ channels in β-cells to close depolarizing the cell. This causes an 
influx in Ca+ and a release of insulin.52 The insulin then acts to remove the glucose from the blood and 
deliver it to the cells. In a fasting state, glucose levels are reduced causing hypoglycemia, which is 
countered through the release of glucose from glycogen stores in the liver. A drop in glucose levels also 
results in glucagon-induced gluconeogenesis, which helps to restore the glucose levels to normal.53,54 
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1.2.1 Impact of T2DM 
T2DM accounts for close to 95% of diabetes patients.55 Most cases go unnoticed and aren’t diagnosed 
for several years; it is estimated that up to a quarter of Americans with T2DM are undiagnosed.44 The 
most common risk factors for T2DM are age and a body mass index (BMI) over 25 kg/m2.56 In many cases 
for people with these risk factors a change in diet can greatly reduce the chances of a diagnosis.57  
T2DM also has a high cost associated with it. Not only do individuals have to suffer from the ailment 
of T2DM but they also have to suffer from medical bills and treatment expenditures. Individuals diagnosed 
with diabetes average medical expenses 2.3 times higher than an individual without diabetes.  In 2012 it 
is estimated that diabetes costs nationwide approached $245 billion.58 These costs reflect on the total 
impact of diabetes and just compound to the physical aspects of the disease.58  
1.2.2 Treatments options for T2DM 
Since T2DM patients are able to make insulin, the treatment is different from a T1DM patient. A 
person with mild T2DM would typically be put on metformin initially. Metformin works to increase insulin 
sensitivity so that the insulin already produced in the body can work properly.59 After metformin 
treatment loses efficacy, typically after the first couple years of treatment, sulfonylureas are added to the 
treatment regimen.60  Sulfonylureas act by directly stimulating insulin secretion. This direct action make 
sulfonylureas very potent but also presents the possibility of hypoglycemia in the case of an overdose. An 
alternative to sulfonylureas are dipeptidyl peptidase IV (DPP-IV) inhibitors.61 DPP-IV inhibitors prevent the 
degradation of incretin hormones which increase insulin levels. This inhibition lets the body release more 
insulin in a glucose dependent manner.62  Metformins, sulfonylureas and DPP-IV inhibitors are all available 
as oral medications, which is why these treatment options are considered first and second line therapies. 
The third line and fourth line treatments are injectable medications. The third line drugs are incretin 
mimetics, which act similar to an incretin hormone in the body and increase insulin levels in a glucose 
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dependent manner.63 The final treatment option is insulin injection, which is only used after no other 
treatments work.  
1.2.3 Incretin Hormones 
A spike in blood glucose levels after ingestion of nutrients causes an increase in insulin levels. This 
glucose dependent control of insulin is known as the incretin effect. The incretin effect is a response to 
peptides, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), 
released in the intestines.64 Activation of the incretin receptor on pancreatic β-cells results in insulin 
release dependent on glucose levels.  
In T2DM patients the incretin effect is greatly reduced.65 This is due in large part to the  
insulinotropic effects of GIP and GLP-1 being either greatly reduced or not present. The insulinotropic 
effects of GIP are no longer present and GIP shows no effect on insulin secretion when administered even 
at pharmacological levels.66,67  GLP-1, however, has been shown to maintain some of its insulinotropic 
effects albeit at a significantly reduced rate compared to non-T2DM people.68 The greater effectiveness 
of GLP-1 to stimulate an insulin release in the presence of T2DM, compared to GIP, has led to the 
treatments utilizing GLP-1R agonism rather than GIPR agonism.  
Of the treatment options for T2DM, only GLP-1 receptor agonist and DPP-IV inhibitors take 
advantage of the incretin effect. Incretin mimetic therapies are able to promote insulin release in a way 
that is glucose dependent which means the body is able to regulate how much insulin is released.69 This 
is an advantage that minimizes the risk of hypoglycemia. Along with minimized hypoglycemia, incretin 
therapies have been shown to induce weight loss, promote β-cell regeneration and improve 
cardiovascular health.70,71,72  
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1.2.3.1 Glucose-dependent insulinotropic peptide 
Glucose-dependent insulinotropic peptide (GIP) was the first incretin hormone found. It was 
initially thought to be only responsible for inhibiting gastric acid secretion but it was later discovered to 
be responsible for insulin secretion. GIP is released from the intestinal K cells post prandially and activates 
the GIP receptor (GIPR), a G-protein coupled receptor (GPCR), located in the pancreatic β-cells resulting 
in an increase in insulin secretion.73 The half-life of GIP is 2-5 min as a result of degradation from DPP-IV.74 
GIP based T2DM therapies have not had much success because of their relatively weak physiological 
effects seen especially when compared to GLP-1.75 There are no current drugs marketed as a GIP agonist, 
but there is research into the effectiveness of GLP-1 and GIP dual agonism.6  
1.2.3.2 Glucagon-like peptide-1 (GLP-1) 
GLP-1 is an incretin hormone in humans which is primarily responsible for controlling insulin levels 
in response to a rise in glucose levels in the blood.76 GLP-1 is produced in the intestinal L cells and is 
typically released post prandially.77 DPP-IV quickly degrades GLP-1 in the intestines resulting in rapid 
clearance (t1/2= ~2 minutes). Most humans have a typical fasting plasma level of GLP-1 of 5-10 pmol/L, 
which can increase upon glucose addition.64   The GLP-1 receptor (GLP-1R) is located in the pancreatic β-
cells as well as the brain, stomach and adipose tissue.78,79,80,81 Although GLP-1 and GIP are both incretin 
hormones and promote the release of insulin there are some key differences. GLP-1, unlike GIP, has been 
shown to inhibit gastric emptying, glucagon secretion and food intake.82,83,84 
1.2.3.3 Exendin 4 (Ex-4) 
Ex-4 is an incretin mimetic, sharing 53% amino acid sequence similarity with GLP-1. Like GLP-1, 
Ex-4 stimulates the release of insulin through agonism of the GLP-1 receptor (GLP-1R) (EC50 33 pM), 
effectively lowering blood glucose levels.85 Unlike GLP-1, Ex-4 is resistant to the enzyme DPP-IV, which 
rapidly cleaves and inactivates GLP-1 in vivo.86 Since DPP-IV cleaves any peptide with an alanine or proline 
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at the second position from the N-terminus, substituting a glycine for the alanine in GLP-1 results in the 
resistance seen in Ex-4. This resistance allows Ex-4 to have a half-life of 2.4 h compared to <2 min as seen 
for GLP-1. Such resistance to DPP-IV does not, however, translate to other proteases, and exenatide 
(synthetic Ex-4) therefore must be administered subcutaneously. 
 
Figure 7. One of the 36 accepted structures of the Ex-4 molecule, pdb1JRJ.87 
1.2.3.3.1 Discovery of Ex-4 
During the late 1980s and early 1990s John Eng, a researcher working for the Veteran Affairs 
Medical center in the Bronx, was searching for peptides in the glucagon superfamily. His search focused 
on peptides found in lizards particularly lizards of the Heloderma family. A narrow search for peptides 
found only in Heloderma suspectum containing the glucagon superfamily characteristic amino-terminal 
histidyl structure (His1) resulted in the discovery of exendin 3, a GLP-1R agonist, in 1990.88 This exciting 
result prompted an expansion on the search to include other species within the Heloderma family. 
Heloderma horridum was found to contain Ex-4, a potent version of exendin 3, with characteristics similar 
to those found in GLP-1 in 1992.89  
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1.2.3.4 Glucagon Receptor Family 
The glucagon receptor superfamily includes the glucagon receptor (GCGR), GLP-1R, glucagon-like 
peptide 2 (GLP-2R) and GIPR.90 These receptors are also part of the larger family of G protein-coupled 
receptors, and as such contain a specific binding domain. Although the glucagon receptor family and 
corresponding peptide agonists share many similarities, each receptor maintains a high affinity for only 
one peptide. However, with careful engineering agonism can be achieved at multiple receptors creating 
dual and triple agonists of the glucagon receptor superfamily.91,92  
There are three classes of GPCRs, class A, B, and C, and members of the glucagon receptor 
superfamily are part of class B.93,94 Class B GPCRs are part of the secretin family and are activated by 
endocrine hormones.95 These receptors contain a 7-transmembrane helical bundle with an N-terminal 
extracellular domain of 120 amino acids.96 Upon agonist binding a GPCR undergoes a conformational 
change resulting in the active state.96 The G protein acts as a signal transducer upon activation and begins 
a signal cascade depending on the subunit and pathway. There are three G protein subunits, α, β, and γ 
and each subunit can be tied to a number of different pathways with the most well know being Gs, Gq, 
and Gi.97 Upon GPCR signaling, β-arrestin proteins bind to the GPCR and desensitize the GPCR, ending the 
signal cascade.98,99    
Members of the glucagon receptor superfamily activate the Gs pathway resulting in an increase 
in cyclic adenosine monophosphate (cAMP). The increase in cAMP production activates the protein kinase 
A (PKA) in the cell. The increase in cAMP and active PKA can be used to follow agonism in receptor 
assays.100  
1.2.3.4.1 Pharmaceutical applications of Ex-4 
Exenatide, a synthetic Ex-4, was approved as a pharmaceutical as the first incretin mimetic under the 
name Byetta in 2005.101  The role of exenatide is to increase insulin production and reduce the need for 
insulin injections. Typical treatment with exenatide is 5 µg injections twice daily for the first month then 
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10 µg injections twice daily.102 The half-life of exenatide is 2.1 hours and it is removed from the blood by 
glomerular filtration and is subsequently degraded by proteases.103   
1.2.4 Obesity  
Obesity and diabetes are comorbidities and approximately 80-95% of patients with T2DM are 
obese.104 However, obesity alone affects significantly more people with estimates reporting over a third 
of Americans as obese.105 The recent rise in obesity and the projections of increased prevalence through 
2050 along with the risk factors associated with the comorbidity of T2DM mean an effective drug to treat 
both is essential.106,107 The most effective treatment of obesity to date is bariatric surgery, which is an 
expensive and invasive to the patient.108  The invasive nature, severity and cost of bariatric surgery limit 
the procedure’s reach.109 However the alternative drugs currently on the market are only capable of 5-
10% weight reduction.110 The effectiveness of weight-loss treatment, especially in single drug treatments, 
is often mitigated by counter-regulatory compensation effects.111  
1.2.4.1 Peptide Tyrosine Tyrosine (PYY) 
Peptide tyrosine tyrosine (PYY) is a peptide is an appetite regulating peptide found in the 
neuropeptide Y hormone family.112 It is secreted from the enteroendocrine L-cells of the intestines 
postprandially. There are two active forms of PYY, PYY(1-36) and PYY(3-36). The initial and short lived PYY 
is PYY(1-36), which has a half-life only a couple of minutes in blood. The short half-life is due to dipeptidyl-
peptidase IV (DPP-IV) which cleaves PYY(1-36) after the second N-terminal amino acid forming PYY(3-36), 
which has a half-life of just under 16 minutes.113 PYY(1-36) is an appetite stimulant which upon truncation 
becomes PYY(3-36), an appetite suppressant, and the major circulating form of PYY.  
1.2.4.1.1 PYY(3-36) function 
PYY(1-36) is cleaved by DPP-IV, which produces PYY(3-36) and eliminates any function at the 
neuropeptide Y1 receptor (NPY1R). PYY(3-36) acts only at the neuropeptide Y2 receptor (NPY2R) which is 
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responsible for appetite suppressing effects. Administration of PYY(3-36) peripherally has been shown to 
reduce food intake in both healthy and obese rodents.114 These results have laid a promising foundation 
for research into PYY(3-36) as an anti-obesity therapy.  
1.2.4.1.2 Neuropeptide Y receptors (NPYR) 
The neuropeptide Y (NPY) receptor family is composed of four receptors (Y1, Y2, Y4 and Y5). Y1 
and Y5 receptors are appetite stimulating and Y2 and Y4 are appetite suppressing.115 The NPY receptors 
are activated by the peptides NPY, pancreatic polypeptide, PYY(1-36), and PYY(3-36). The NPY receptors 
are class A GPCRs, which generally activate either Gi or Gq pathways. The Gq protein activates a cascade 
which raises Ca2+ levels which can be followed through in vitro assays using Fura-2, a Ca2+ binding dye.116 
The Gi pathway causes a decrease in cAMP levels, which can be difficult to detect so a promiscuous Gq 
protein is often introduced to produce a positive response.117  
1.2.4.1.3 PYY(3-36) pharmaceutical applications 
PYY(3-36) has potential as a pharmacological peptide for appetite control and obesity. The first 
research to highlight the role of PYY(3-36) was published by Batterham in 2002, which showed food intake 
reductions of up to 30%.112 Since that paper there has been no shortage of research invested in finding a 
drug involving PYY(3-36), however no drugs have come to market. This lack of clinical translation is due to 
two characteristics of PYY(3-36): the first is the nausea associated with administration of the peptide and 
the second and most important factor is that the body is able to overcome its the appetite suppressing 
abilities after a couple of days of treatment.118,119  
Therapy involving PYY(3-36) has to be approached from more than one direction to compensate 
for the body’s ability to overcome the PYY(3-36) signaling. This can be approached through a combination 
therapy involving multiple peptides or through a single peptide targeting multiple targets with the ability 
to suppress appetite.   
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1.2.4.2 Combination therapy for diabetes and obesity treatment 
Bariatric surgery has been around for decades and is established as a very effective way to treat 
obesity. Recently it has been realized that bariatric surgery is also an effective way to treat T2DM.120 
Although the exact mechanisms which make bariatric surgery so effective are still relatively unknown, it 
is known that both GLP-1 and PYY(3-36) levels are considerably higher after surgery.121 Replication of the 
effect caused on hormones after bariatric surgery through medication would provide a great tool for 
treating both obesity and diabetes.  
1.2.4.3 Summary 
Diabetes is a disease that effects almost a tenth of all Americans, and though it is mostly controlled 
with proper medical care there is still room for improvement. Many treatment options for more severe 
cases of diabetes come with unpleasant side effects or an invasive method of administration. Changes in 
administration from injection to oral would do a great deal to improve patient compliance with third line 
medications. Changes in hydrophobicity could alter brain uptake and minimize unwanted side effects. The 
nature of B12 makes it a suitable candidate to alter both of these characteristics. This gives a B12-Ex-4 
conjugate the potential to be an oral diabetes medication with limited side effects.  
The comorbidity of obesity and diabetes is particularly concerning and although there are methods to 
control diabetes there are far fewer options to control obesity. Although Ex-4 isn’t approved for weight 
loss it is one of the side effects to the treatment. Enhancements to the appetite suppressing ability of Ex-
4 without diminishing its ability to control glucose levels could lead to a diabetes/obesity treatment 
combined in one drug. PYY is a natural peptide designed to suppress appetite in humans, however the 
short half-life of PYY makes it unsuitable as a pharmaceutical. Tailoring Ex-4 to activate both the GLP-1R 
and NPY2R by constructing a hybrid Ex-4/PYY peptide could lead to a single peptide with dual agonism at 
both GLP-1R and NPY2R.  
17
Modifications to Ex-4 either through B12 conjugation or sequence manipulation could provide 
important improvements to the pharmacokinetics and pharmacodynamics of Ex-4. Success in this work 
could open the doors to both B12 chemistry and Ex-4 chemistry. B12 modification to Ex-4 could provide a 
method to mitigate side effects and be used as a tool in pharmaceutical peptide chemistry to alter brain 
uptake. A coagonist of GLP-1R and NPY2R drug would provide a method for treating both diabetes and 
obesity, simultaneously.  
1.3 References 
1. Kennedy, D. O., B Vitamins and the Brain: Mechanisms, Dose and Efficacy—A Review. Nutrients 
2016, 8 (2), 68. 
2. Stubbe, J., Binding site revealed of nature's most beautiful cofactor. Science 1994, 266 (5191), 
1663-1664. 
3. Giedyk, M.; Goliszewska, K.; Gryko, D., Vitamin B12 catalysed reactions. Chemical Society Reviews 
2015, 44 (11), 3391-3404. 
4. Abeles, R. H.; Dolphin, D., The vitamin B12 coenzyme. Accounts of Chemical Research 1976, 9 (3), 
114-120. 
5. Nielsen, M. J.; Rasmussen, M. R.; Andersen, C. B.; Nexo, E.; Moestrup, S. K., Vitamin B12 transport 
from food to the body's cells--a sophisticated, multistep pathway. Nat Rev Gastroenterol Hepatol 2012, 9 
(6), 345-354. 
6. Finan, B.; Müller, T. D.; Clemmensen, C.; Perez-Tilve, D.; DiMarchi, R. D.; Tschöp, M. H., 
Reappraisal of GIP Pharmacology for Metabolic Diseases. Trends in Molecular Medicine 22 (5), 359-376. 
7. Brey, R.; Banner, C.; Wolf, J., Cloning of multiple genes involved with cobalamin (Vitamin B12) 
biosynthesis in Bacillus megaterium. Journal of bacteriology 1986, 167 (2), 623-630. 
8. Crouzet, J.; Cauchois, L.; Blanche, F.; Debussche, L.; Thibaut, D.; Rouyez, M.; Rigault, S.; Mayaux, 
J.; Cameron, B., Nucleotide sequence of a Pseudomonas denitrificans 5.4-kilobase DNA fragment 
containing five cob genes and identification of structural genes encoding S-adenosyl-L-methionine: 
uroporphyrinogen III methyltransferase and cobyrinic acid a, c-diamide synthase. Journal of bacteriology 
1990, 172 (10), 5968-5979. 
9. Crouzet, J.; Levy-Schil, S.; Cameron, B.; Cauchois, L.; Rigault, S.; Rouyez, M.; Blanche, F.; 
Debussche, L.; Thibaut, D., Nucleotide sequence and genetic analysis of a 13.1-kilobase-pair Pseudomonas 
denitrificans DNA fragment containing five cob genes and identification of structural genes encoding Cob 
(I) alamin adenosyltransferase, cobyric acid synthase, and bifunctional cobinamide kinase-cobinamide 
phosphate guanylyltransferase. Journal of bacteriology 1991, 173 (19), 6074-6087. 
18
10. Roth, J. R.; Lawrence, J. G.; Rubenfield, M.; Kieffer-Higgins, S.; Church, G. M., Characterization of 
the cobalamin (vitamin B12) biosynthetic genes of Salmonella typhimurium. Journal of bacteriology 1993, 
175 (11), 3303-3316. 
11. Petrus, A. K.; Fairchild, T. J.; Doyle, R. P., Traveling the Vitamin B12 Pathway: Oral Delivery of 
Protein and Peptide Drugs. Angewandte Chemie International Edition 2009, 48 (6), 1022-1028. 
12. Herbert, V., Recommended dietary intakes (RDI) of vitamin B-12 in humans. The American Journal 
of Clinical Nutrition 1987, 45 (4), 671-678. 
13. Medicine, I. o., Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, 
Vitamin B12, Pantothenic Acid, Biotin, and Choline. The National Academies Press: Washington, DC, 1998; 
p 592. 
14. Shemin, D.; Bray, R. C., The biosynthesis of the corrin structure of vitamin B12*. Annals of the New 
York Academy of Sciences 1964, 112 (2), 615-621. 
15. Wuerges, J.; Geremia, S.; Randaccio, L., Structural study on ligand specificity of human vitamin 
B12 transporters. Biochemical Journal 2007, 403 (Pt 3), 431-440. 
16. Tran, M. T. Q.; Stürup, S.; Lambert, I. H.; Gammelgaard, B.; Furger, E.; Alberto, R., Cellular uptake 
of metallated cobalamins. Metallomics 2016, 8 (3), 298-304. 
17. Bizzaro, N.; Antico, A., Diagnosis and classification of pernicious anemia. Autoimmunity Reviews 
2014, 13 (4–5), 565-568. 
18. Sinclair, L., Recognizing, treating and understanding pernicious anaemia. Journal of the Royal 
Society of Medicine 2008, 101 (5), 262-264. 
19. Combe, J. S., History of a case of anaemia. Transactions of the Medico-Chirurgical Society of 
Edinburgh 1824, 1, 194-204. 
20. Whipple, G. H.; Robscheit-Robbins, F. S., THe regeneration of blood in anemia. Journal of the 
American Medical Association 1925, 85 (1), 36-37. 
21. Minot, G. R.; Murphy, W. P., Treatment of pernicious anemia by a special diet. The Yale Journal of 
Biology and Medicine 1926, 74 (5), 341-353. 
22. Okuda, K., Discovery of vitamin B12 in the liver and its absorption factor in the stomach: A 
historical review. Journal of Gastroenterology and Hepatology 1999, 14 (4), 301-308. 
23. Castle, W. B., Observations on the etiologic relationship of achylia gastrica to pernicious anemia. 
The American Journal of the Medical Sciences 1929, 178 (6), 748-763. 
24. Castle, W. B.; Townsend, W. C.; HEATH, C. W., Observations on the etiologic relationship of achylia 
gastrica to pernicious anemia.: iii. the nature of the reaction between normal human gastric juice and beef 
muscle leading to clinical improvement and increased blood formation similar to the effect of liver 
feeding. The American Journal of the Medical Sciences 1930, 180 (3), 305-335. 
19
25. Scott, J. M.; Molloy, A. M., The Discovery of Vitamin B12. Annals of Nutrition and Metabolism 
2012, 61 (3), 239-245. 
26. Rickes, E. L.; Brink, N. G.; Koniuszy, F. R.; Wood, T. R.; Folkers, K., Crystalline vitamin B12. American 
Association for the Advancement of Science. Science 1948, 107, 396-397. 
27. Smith, E. L., Purification of anti-pernicious anaemia factors from liver. Nature 1948, 161 (4095), 
638-638. 
28. D. C.  Hogdkin; FRS; Kamper, J.; Mackay, M.; Pickworth, J.; Trueblood, K.; White, J., Structure of 
vitamin B12. Nature 1956, 178, 64-66. 
29. Guéant, J.-L.; Caillerez-Fofou, M.; Battaglia-Hsu, S.; Alberto, J.-M.; Freund, J.-N.; Dulluc, I.; Adjalla, 
C.; Maury, F.; Merle, C.; Nicolas, J.-P.; Namour, F.; Daval, J.-L., Molecular and cellular effects of vitamin 
B12 in brain, myocardium and liver through its role as co-factor of methionine synthase. Biochimie 2013, 
95 (5), 1033-1040. 
30. Takahashi-Iñiguez, T.; García-Hernandez, E.; Arreguín-Espinosa, R.; Flores, M. E., Role of vitamin 
B12 on methylmalonyl-CoA mutase activity. Journal of Zhejiang University SCIENCE B 2012, 13 (6), 423-
437. 
31. Fedosov, S. N.; Fedosova, N. U.; Kräutler, B.; Nexø, E.; Petersen, T. E., Mechanisms of 
Discrimination between Cobalamins and Their Natural Analogues during Their Binding to the Specific B12-
Transporting Proteins. Biochemistry 2007, 46 (21), 6446-6458. 
32. Furger, E.; Fedosov, S. N.; Launholt Lildballe, D.; Waibel, R.; Schibli, R.; Nexo, E.; Fischer, E., 
Comparison of Recombinant Human Haptocorrin Expressed in Human Embryonic Kidney Cells and Native 
Haptocorrin. PLoS ONE 2012, 7 (5), e37421. 
33. Furger, E.; Frei, D. C.; Schibli, R.; Fischer, E.; Prota, A. E., Structural Basis for Universal Corrinoid 
Recognition by the Cobalamin Transport Protein Haptocorrin. The Journal of Biological Chemistry 2013, 
288 (35), 25466-25476. 
34. Allen, R. H.; Seetharam, B.; Podell, E.; Alpers, D. H., Effect of Proteolytic Enzymes on the Binding 
of Cobalamin to R Protein and Intrinsic Factor: In Vitro Evidence That A Failure To Partially Degrader 
Protein Is Responsible For Cobalamin Malabsorption In Pancreatic Insufficiency. Journal of Clinical 
Investigation 1978, 61 (1), 47-54. 
35. (a) Alpers, D. H.; Russell-Jones, G., Gastric intrinsic factor: The gastric and small intestinal stages 
of cobalamin absorption. A personal journey. Biochimie 2013, 95 (5), 989-994; (b) Mathews, F. S.; Gordon, 
M. M.; Chen, Z.; Rajashankar, K. R.; Ealick, S. E.; Alpers, D. H.; Sukumar, N., Crystal structure of human 
intrinsic factor: cobalamin complex at 2.6-A resolution. Proceedings of the National Academy of Sciences 
of the United States of America 2007, 104 (44), 17311-17316. 
36. Kozyraki, R.; Fyfe, J.; Kristiansen, M.; Gerdes, C.; Jacobsen, C.; Cui, S.; Christensen, E. I.; Aminoff, 
M.; de la Chapelle, A.; Krahe, R., The intrinsic factor–vitamin B12 receptor, cubilin, is a high-affinity 
apolipoprotein AI receptor facilitating endocytosis of high-density lipoprotein. Nature medicine 1999, 5 
(6), 656-661. 
20
37. Gordon, M. M.; Howard, T.; Becich, M. J.; Alpers, D. H., Cathepsin L mediates intracellular ileal 
digestion of gastric intrinsic factor. American Journal of Physiology - Gastrointestinal and Liver Physiology 
1995, 268 (1), G33-G40. 
38. Wuerges, J.; Garau, G.; Geremia, S.; Fedosov, S. N.; Petersen, T. E.; Randaccio, L., Structural basis 
for mammalian vitamin B(12) transport by transcobalamin. Proceedings of the National Academy of 
Sciences of the United States of America 2006, 103 (12), 4386-4391. 
39. Lai, S.-C.; Nakayama, Y.; Sequeira, J. M.; Wlodarczyk, B. J.; Cabrera, R. M.; Finnell, R. H.; Bottiglieri, 
T.; Quadros, E. V., The transcobalamin receptor knockout mouse: a model for vitamin B12 deficiency in 
the central nervous system. The FASEB Journal 2013, 27 (6), 2468-2475. 
40. Workinger, J. L.; Doyle, R. P., Vitamin B12: advances and insights; Vitamin B12 and Drug 
Development. Science Publishers 2016. 
41. Clardy, S. M.; Allis, D. G.; Fairchild, T. J.; Doyle, R. P., Vitamin B12 in drug delivery: breaking through 
the barriers to a B12 bioconjugate pharmaceutical. Expert opinion on drug delivery 2011, 8 (1), 127-140. 
42. Francis, M. F.; Cristea, M.; Winnik, F. M., Exploiting the vitamin B12 pathway to enhance oral drug 
delivery via polymeric micelles. Biomacromolecules 2005, 6 (5), 2462-2467. 
43. Petrus, A. K.; Vortherms, A. R.; Fairchild, T. J.; Doyle, R. P., Vitamin B12 as a carrier for the oral 
delivery of insulin. ChemMedChem 2007, 2 (12), 1717-1721. 
44. 2016 National Diabetes Fact Sheet, Centers for Disease Control and Prevention. . 
45. Daneman, D., Type 1 diabetes. The Lancet 367 (9513), 847-858. 
46. Dawed, A. Y.; Zhou, K.; Pearson, E. R., Pharmacogenetics in type 2 diabetes: influence on response 
to oral hypoglycemic agents. Pharmacogenomics and Personalized Medicine 2016, 9, 17-29. 
47. Petrak, F.; Herpertz, S.; Stridde, E.; Pfützner, A., Psychological Insulin Resistance in Type 2 Diabetes 
Patients Regarding Oral Antidiabetes Treatment, Subcutaneous Insulin Injections, or Inhaled Insulin. 
Diabetes technology & therapeutics 2013, 15 (8), 702-710. 
48. Kahn, S. E., The relative contributions of insulin resistance and beta-cell dysfunction to the 
pathophysiology of Type 2 diabetes. Diabetologia 2003, 46 (1), 3-19. 
49. Habegger, K. M.; Heppner, K. M.; Geary, N.; Bartness, T. J.; DiMarchi, R.; Tschop, M. H., The 
metabolic actions of glucagon revisited. Nat Rev Endocrinol 2010, 6 (12), 689-697. 
50. Zoungas, S.; Patel, A.; Chalmers, J.; de Galan, B. E.; Li, Q.; Billot, L.; Woodward, M.; Ninomiya, T.; 
Neal, B.; MacMahon, S., Severe hypoglycemia and risks of vascular events and death. New England Journal 
of Medicine 2010, 363 (15), 1410-1418. 
51. Klein, R., Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes care 
1995, 18 (2), 258-268. 
21
52. Henquin, J. C., Triggering and amplifying pathways of regulation of insulin secretion by glucose. 
Diabetes 2000, 49 (11), 1751-1760. 
53. Ozcan, L.; Wong, Catherine C. L.; Li, G.; Xu, T.; Pajvani, U.; Park, Sung Kyu R.; Wronska, A.; Chen, 
B.-X.; Marks, Andrew R.; Fukamizu, A.; Backs, J.; Singer, Harold A.; Yates Iii, John R.; Accili, D.; Tabas, I., 
Calcium Signaling through CaMKII Regulates Hepatic Glucose Production in Fasting and Obesity. Cell 
Metabolism 2012, 15 (5), 739-751. 
54. Herzig, S.; Long, F.; Jhala, U. S.; Hedrick, S.; Quinn, R.; Bauer, A.; Rudolph, D.; Schutz, G.; Yoon, C.; 
Puigserver, P.; Spiegelman, B.; Montminy, M., CREB regulates hepatic gluconeogenesis through the 
coactivator PGC-1. Nature 2001, 413 (6852), 179-183. 
55. International Diabetes Federation. Diabetes atlas. International Diabetes Federation, 2015. 
56. Eckel, N.; Mühlenbruch, K.; Meidtner, K.; Boeing, H.; Stefan, N.; Schulze, M. B., Characterization 
of metabolically unhealthy normal-weight individuals: Risk factors and their associations with type 2 
diabetes. Metabolism 2015, 64 (8), 862-871. 
57. McGinley, S. K.; Armstrong, M. J.; Boulé, N. G.; Sigal, R. J., Effects of exercise training using 
resistance bands on glycaemic control and strength in type 2 diabetes mellitus: a meta-analysis of 
randomised controlled trials. Acta Diabetologica 2015, 52 (2), 221-230. 
58. Association, A. D., Economic Costs of Diabetes in the U.S. in 2012. Diabetes Care 2013. 
59. Kajbaf, F.; De Broe, M. E.; Lalau, J.-D., Therapeutic Concentrations of Metformin: A Systematic 
Review. Clinical Pharmacokinetics 2016, 55 (4), 439-459. 
60. Chan, S. P.; Colagiuri, S., Systematic review and meta-analysis of the efficacy and hypoglycemic 
safety of gliclazide versus other insulinotropic agents. Diabetes Research and Clinical Practice 2015, 110 
(1), 75-81. 
61. Eriksson, J. W.; Bodegard, J.; Nathanson, D.; Thuresson, M.; Nyström, T.; Norhammar, A., 
Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of 
severe hypoglycemia, cardiovascular events, and all-cause mortality. Diabetes Research and Clinical 
Practice 2016, 117, 39-47. 
62. Ahren, B., DPP-4 inhibitors. Best practice & research. Clinical endocrinology & metabolism 2007, 
21 (4), 517-533. 
63. Nauck, M. A.; Baranov, O.; Ritzel, R. A.; Meier, J. J., Do current incretin mimetics exploit the full 
therapeutic potential inherent in GLP-1 receptor stimulation? Diabetologia 2013, 56 (9), 1878-1883. 
64. Baggio, L. L.; Drucker, D. J., Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132 (6), 
2131-57. 
65. Eriksen, M.; Jensen, D. H.; Tribler, S.; Holst, J. J.; Madsbad, S.; Krarup, T., Reduction of 
insulinotropic properties of GLP-1 and GIP after glucocorticoid-induced insulin resistance. Diabetologia 
2015, 58 (5), 920-928. 
22
66. Kim, W.; Egan, J. M., The Role of Incretins in Glucose Homeostasis and Diabetes Treatment. 
Pharmacological Reviews 2008, 60 (4), 470-512. 
67. Vilsbøll, T.; Krarup, T.; Madsbad, S.; Holst, J., Defective amplification of the late phase insulin 
response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002, 45 (8), 1111-1119. 
68. Kjems, L. L.; Holst, J. J.; Vølund, A.; Madsbad, S., The Influence of GLP-1 on Glucose-Stimulated 
Insulin Secretion. Effects on β-Cell Sensitivity in Type 2 and Nondiabetic Subjects 2003, 52 (2), 380-386. 
69. Nauck, M., Incretin therapies: highlighting common features and differences in the modes of 
action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes, 
Obesity and Metabolism 2016, 18 (3), 203-216. 
70. Tamura, K.; Minami, K.; Kudo, M.; Iemoto, K.; Takahashi, H.; Seino, S., Liraglutide Improves 
Pancreatic Beta Cell Mass and Function in Alloxan-Induced Diabetic Mice. PLoS ONE 2015, 10 (5), 
e0126003. 
71. Kostev, K.; Rex, J.; Rockel, T.; Heilmaier, C., Effects of selected antidiabetics on weight loss – A 
retrospective database analysis. Primary Care Diabetes 2015, 9 (1), 74-77. 
72. White, W. B.; Baker, W. L., Cardiovascular Effects of Incretin-Based Therapies. Annual Review of 
Medicine 2016, 67 (1), 245-260. 
73. Jorde, R.; Burhol, P. G.; Waldum, H. L.; Schulz, T. B.; Lygren, I.; Florholmen, J., Diurnal variation of 
plasma gastric inhibitory polypeptide in man. Scandinavian journal of gastroenterology 1980, 15 (5), 617-
619. 
74. Tatarkiewicz, K.; Hargrove, D. M.; Jodka, C. M.; Gedulin, B. R.; Smith, P. A.; Hoyt, J. A.; Lwin, A.; 
Collins, L.; Mamedova, L.; Levy, O. E.; D'Souza, L.; Janssen, S.; Srivastava, V.; Ghosh, S. S.; Parkes, D. G., A 
novel long‐acting glucose‐dependent insulinotropic peptide analogue: enhanced efficacy in normal 
and diabetic rodents. Diabetes, Obesity and Metabolism 2014, 16 (1), 75-85. 
75. Lebovitz, H. E., Incretin-based therapies: facing the realities of benefits versus side effects. 
Diabetes technology & therapeutics 2013, 15 (11), 909-913. 
76. Kreymann, B.; Williams, G.; Ghatei, M. A.; Bloom, S. R., Glucagon-like peptide-1 7-36: a 
physiological incretin in man. Lancet (London, England) 1987, 2 (8571), 1300-4. 
77. Elliott, R. M.; Morgan, L. M.; Tredger, J. A.; Deacon, S.; Wright, J.; Marks, V., Glucagon-like peptide-
1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient 
ingestion in man: acute post-prandial and 24-h secretion patterns. The Journal of endocrinology 1993, 138 
(1), 159-166. 
78. Hörsch, D.; Göke, R.; Eissele, R.; Michel, B.; Göke, B., Reciprocal cellular distribution of glucagon-
like peptide-1 (GLP-1) immunoreactivity and GLP-1 receptor mRNA in pancreatic islets of rat. Pancreas 
1997, 14 (3), 290-294. 
23
79. Göke, R.; Larsen, P. J.; Mikkelsen, J. D.; Sheikh, S. P., Distribution of GLP‐1 binding sites in the rat 
brain: evidence that exendin‐4 is a ligand of brain GLP‐1 binding sites. European Journal of 
Neuroscience 1995, 7 (11), 2294-2300. 
80. Uttenthal, L.; Blazquez, E., Characterization of high‐affinity receptors for truncated glucagon‐
like peptide‐1 in rat gastric glands. FEBS letters 1990, 262 (1), 139-141. 
81. Valverde, I.; Merida, E.; Delgado, E.; Trapote, M.; Villanueva-Penacarrillo, M., Presence and 
characterization of glucagon-like peptide-1 (7-36) amide receptors in solubilized membranes of rat 
adipose tissue. Endocrinology 1993, 132 (1), 75-79. 
82. Drucker, D. J.; Nauck, M. A., The incretin system: glucagon-like peptide-1 receptor agonists and 
dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet 368 (9548), 1696-1705. 
83. Willms, B.; Werner, J.; Holst, J. J.; Orskov, C.; Creutzfeldt, W.; Nauck, M. A., Gastric emptying, 
glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like 
peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. The Journal of Clinical 
Endocrinology & Metabolism 1996, 81 (1), 327-332. 
84. Gutzwiller, J.-P.; Göke, B.; Drewe, J.; Hildebrand, P.; Ketterer, S.; Handschin, D.; Winterhalder, R.; 
Conen, D.; Beglinger, C., Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999, 
44 (1), 81-86. 
85. Thorens, B.; Porret, A.; Bühler, L.; Deng, S.-P.; Morel, P.; Widmann, C., Cloning and Functional 
Expression of the Human Islet GLP-1 Receptor: Demonstration That Exendin-4 Is an Agonist and Exendin-
(9–39) an Antagonist of the Receptor. Diabetes 1993, 42 (11), 1678-1682. 
86. Furman, B. L., The development of Byetta (exenatide) from the venom of the Gila monster as an 
anti-diabetic agent. Toxicon : official journal of the International Society on Toxinology 2012, 59 (4), 464-
471. 
87. Neidigh, J. W.; Fesinmeyer, R. M.; Prickett, K. S.; Andersen, N. H., Exendin-4 and Glucagon-like-
peptide-1:  NMR Structural Comparisons in the Solution and Micelle-Associated States. Biochemistry 2001, 
40 (44), 13188-13200. 
88. Eng, J.; Andrews, P. C.; Kleinman, W. A.; Singh, L.; Raufman, J. P., Purification and structure of 
exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom. Journal of 
Biological Chemistry 1990, 265 (33), 20259-62. 
89. Eng, J., Isolation and Characterization of Exendin-4, an Exendin-3 Analogue from Heloderma 
suspetum Venom. Journal of Biological Chemistry 1992, 267 (11), 4. 
90. Brubaker, P. L.; Drucker, D. J., Structure-function of the glucagon receptor family of G protein-
coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors & channels 2002, 8 (3-4), 
179-188. 
24
91. Reimann, F.; Gribble, F. M., G protein-coupled receptors as new therapeutic targets for type 2 
diabetes. Diabetologia 2016, 59 (2), 229-233. 
92. Finan, B.; Yang, B.; Ottaway, N.; Smiley, D. L.; Ma, T.; Clemmensen, C.; Chabenne, J.; Zhang, L.; 
Habegger, K. M.; Fischer, K.; Campbell, J. E.; Sandoval, D.; Seeley, R. J.; Bleicher, K.; Uhles, S.; Riboulet, W.; 
Funk, J.; Hertel, C.; Belli, S.; Sebokova, E.; Conde-Knape, K.; Konkar, A.; Drucker, D. J.; Gelfanov, V.; Pfluger, 
P. T.; Muller, T. D.; Perez-Tilve, D.; DiMarchi, R. D.; Tschop, M. H., A rationally designed monomeric peptide 
triagonist corrects obesity and diabetes in rodents. Nat Med 2015, 21 (1), 27-36. 
93. Siu, F. Y.; He, M.; de Graaf, C.; Han, G. W.; Yang, D.; Zhang, Z.; Zhou, C.; Xu, Q.; Wacker, D.; Joseph, 
J. S.; Liu, W.; Lau, J.; Cherezov, V.; Katritch, V.; Wang, M.-W.; Stevens, R. C., Structure of the human 
glucagon class B G-protein-coupled receptor. Nature 2013, 499 (7459), 444-449. 
94. Kirkpatrick, A.; Heo, J.; Abrol, R.; Goddard, W. A., Predicted structure of agonist-bound glucagon-
like peptide 1 receptor, a class B G protein-coupled receptor. Proceedings of the National Academy of 
Sciences 2012, 109 (49), 19988-19993. 
95. Lee, S.-M.; Booe, J. M.; Pioszak, A. A., Structural insights into ligand recognition and selectivity for 
classes A, B, and C GPCRs. European Journal of Pharmacology 2015, 763, Part B, 196-205. 
96. Li, Y.; Sun, J.; Li, D.; Lin, J., Activation and conformational dynamics of a class B G-protein-coupled 
glucagon receptor. Physical Chemistry Chemical Physics 2016, 18 (18), 12642-12650. 
97. Neves, S. R.; Ram, P. T.; Iyengar, R., G Protein Pathways. Science 2002, 296 (5573), 1636-1639. 
98. Miller, W. E.; Lefkowitz, R. J., Expanding roles for β-arrestins as scaffolds and adapters in GPCR 
signaling and trafficking. Current Opinion in Cell Biology 2001, 13 (2), 139-145. 
99. Smith, J. S.; Rajagopal, S., The β-Arrestins: Multifunctional Regulators of G Protein-coupled 
Receptors. Journal of Biological Chemistry 2016, 291 (17), 8969-8977. 
100. Holz, G. G.; Chepurny, O.; Leech, C.; Roe, M.; Xiaodong, C., High-throughput FRET assays for fast 
time-dependent detection of cyclic AMP in pancreatic beta cells. CRC Press, Taylor & Francis Group: Boca 
Raton, FL: 2015. 
101. Bond, A. In Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus, Baylor 
University Medical Center. Proceedings, Baylor University Medical Center: 2006; p 281. 
102. Byetta, US Full Prescribing Information. 
103. Grossman, S. S., Pathophysiological and Pharmacological Rationale for the Use of Exenatide Once 
Weekly in Patients with Type 2 Diabetes. Advances in Therapy 2014, 31 (3), 247-263. 
104. Astrup, A., Healthy lifestyles in Europe: prevention of obesity and type II diabetes by diet and 
physical activity. Public health nutrition 2001, 4 (2b), 499-515. 
105. Ogden, C. L.; Carroll, M. D.; Kit, B. K.; Flegal, K. M., Prevalence of obesity in the United States, 
2009-2010. NCHS data brief 2012,  (82), 1-8. 
25
106. Bray, G. A., Medical treatment of obesity: the past, the present and the future. Best practice & 
research Clinical gastroenterology 2014, 28 (4), 665-684. 
107. Solas, M.; Milagro, F. I.; Martínez-Urbistondo, D.; Ramirez, M. J.; Martínez, J. A., Precision Obesity 
Treatments Including Pharmacogenetic and Nutrigenetic Approaches. Trends in Pharmacological Sciences 
2016, 37 (7), 575-593. 
108. Münzberg, H.; Laque, A.; Yu, S.; Rezai-Zadeh, K.; Berthoud, H. R., Appetite and body weight 
regulation after bariatric surgery. Obesity Reviews 2015, 16, 77-90. 
109. Pories, W. J., Bariatric Surgery: Risks and Rewards. The Journal of Clinical Endocrinology and 
Metabolism 2008, 93 (11 Suppl 1), S89-S96. 
110. Daneschvar, H. L.; Aronson, M. D.; Smetana, G. W., FDA-Approved Anti-Obesity Drugs in the 
United States. The American Journal of Medicine 2016, 129 (8), 879.e1-879.e6. 
111. Kakkar, A. K.; Dahiya, N., Drug treatment of obesity: Current status and future prospects. 
European journal of internal medicine 2015, 26 (2), 89-94. 
112. Batterham, R. L.; Cowley, M. A.; Small, C. J.; Herzog, H.; Cohen, M. A.; Dakin, C. L.; Wren, A. M.; 
Brynes, A. E.; Low, M. J.; Ghatei, M. A.; Cone, R. D.; Bloom, S. R., Gut hormone PYY3-36 physiologically 
inhibits food intake. Nature 2002, 418 (6898), 650-654. 
113. Torang, S.; Bojsen-Moller, K. N.; Svane, M. S.; Hartmann, B.; Rosenkilde, M. M.; Madsbad, S.; Holst, 
J. J., In vivo and in vitro degradation of peptide YY3-36 to inactive peptide YY3-34 in humans. American 
journal of physiology. Regulatory, integrative and comparative physiology 2016, 310 (9), R866-874. 
114. McGowan, B. M.; Bloom, S. R., Gut hormones regulating appetite and metabolism. Drug Discovery 
Today: Therapeutic Strategies 2007, 4 (2), 147-151. 
115. Zac-Varghese, S.; De Silva, A.; Bloom, S. R., Translational studies on PYY as a novel target in obesity. 
Current Opinion in Pharmacology 2011, 11 (6), 582-585. 
116. Roe, M.; Lemasters, J.; Herman, B., Assessment of Fura-2 for measurements of cytosolic free 
calcium. Cell calcium 1990, 11 (2-3), 63-73. 
117. Xing, H.; Tran, H.-C.; Knapp, T. E.; Negulescu, P. A.; Pollok, B. A., A Fluorescent Reporter Assay for 
the Detection of Ligands Acting Through GI Protein-Coupled Receptors. Journal of Receptors and Signal 
Transduction 2000, 20 (4), 189-210. 
118. Sloth, B.; Holst, J. J.; Flint, A.; Gregersen, N. T.; Astrup, A., Effects of PYY1–36 and PYY3–36 on 
appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. 
American Journal of Physiology - Endocrinology and Metabolism 2007, 292 (4), E1062-E1068. 
119. Henry, K. E.; Elfers, C. T.; Burke, R. M.; Chepurny, O. G.; Holz, G. G.; Blevins, J. E.; Roth, C. L.; Doyle, 
R. P., Vitamin B12 Conjugation of Peptide-YY3–36 Decreases Food Intake Compared to Native Peptide-
YY3–36 Upon Subcutaneous Administration in Male Rats. Endocrinology 2015, 0 (0), en.2014-1825. 
26
120. Schauer , P. R.; Bhatt , D. L.; Kirwan , J. P.; Wolski , K.; Brethauer , S. A.; Navaneethan , S. D.; 
Aminian , A.; Pothier , C. E.; Kim , E. S. H.; Nissen , S. E.; Kashyap , S. R., Bariatric Surgery versus Intensive 
Medical Therapy for Diabetes — 3-Year Outcomes. New England Journal of Medicine 2014, 370 (21), 2002-
2013. 
121. Arble, D. M.; Sandoval, D. A.; Seeley, R. J., Mechanisms underlying weight loss and metabolic 
improvements in rodent models of bariatric surgery. Diabetologia 2015, 58 (2), 211-220. 
 
27
Chapter 2: Synthesis, characterization, in vitro and in vivo analysis of B12 conjugated to Exendin 4  
The work reported in this chapter will be submitted to Diabetes with the title “Vitamin B12 conjugation 
of exendin-4 abrogates CNS induced nausea and food intake reduction and reverses hyperglycemic 
response in the rat” and coauthors: Ron L. Bonaccorso, Clinton L. Elfers, Elizabeth G Mietlicki-Baase, 
George G. Holz, Matthew Hayes, Christian L. Roth and Robert P. Doyle 
 
The first trials of the in vivo glucose tolerance tests and food intake studies reported in this chapter 
were completed by me while visiting Seattle Children’s Research Institute (photo shown above).     
2.1 Introduction 
Controlling glucose levels is the goal of diabetes treatment. First and second line drugs, such as 
metformin and sulfonylureas, are effective, safe, and noninvasive.1 Third line drugs, though effective and 
very safe, are administered only through subcutaneous injection, leading to low patient compliance, and 
often come with unpleasant side effects.2 Nausea is reported in 50% of the patients taking exenatide, 
synthetic Ex-4, for example.3  This side effect is hypothesized to be a result of Ex-4 agonism of GLP-1R in 
the brain at the arcuate nucleus (AC) of the hypothalmus.4 GLP-1Rs in the brain are also responsible for 
the weight reduction associated with GLP-1 mimetics, but the pancreatic receptors are used to control 
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glucose levels and insulin release.5,6 If brain uptake can be shut down or reduced, both nausea and weight 
loss will be decreased. 
Ex-4 is able to rapidly cross the blood brain barrier (BBB), due to its lipophilic properties.7 Ex-4 brain 
uptake studies have shown that almost 90% of Ex-4 reaches the brain.8 To prevent BBB passage the 
lipophilicity of Ex-4 must be altered. One way to do this is through conjugation with a lipophobic molecule. 
B12 transport across membranes is receptor mediated and not capable of passive diffusion which make it 
a good candidate for conjugation and subsequently preventing or at least inhibiting brain uptake.9 Only 
TCII bound B12 and not HC bound B12, which composes almost 25% of the total B12 binding protein in blood, 
is able to pass through the blood brain barrier and only a third of serum B12 enters the brain.10,11  
2.2 Design and syntheses of B12-Ex-4 conjugates (7-10) 
Previously in the Doyle lab, B12 had been functionalized with a carboxylic acid through modification of 
the 5’ hydroxyl group of the ribose moiety.12 Oxidation at this position through use of 2-iodoxybenzoic 
acid (IBX) allows for further modification and higher yielding peptide conjugations (over 90 percent yield).  
2.2.1 Synthesis and characterization of B12-Ex-4 conjugates (7-10) 
B12, as cyanocobalamin (1), had to be modified in a way that would allow high yielding conjugation 
between it and Ex-4. This was achieved by modifying the ribose hydroxyl group. B12 was initially 
functionalized to a carboxylic acid.12 From the carboxylic acid a carbon linker and alkyne functional group 
could be formed.  
2.2.1.1 B12 modification of the 5’ hydroxyl to a carboxylic acid 
This is done by converting the 5’ hydroxyl to a carboxylic acid as shown in Figure 1. Modifications 
are done at this position so that binding to the transfer proteins remains unhampered. This reaction is 
done using IBX and 2-hydroxypyridine (HYP). The primary alcohol is successfully converted to a carboxylic 
acid producing B12-CA (2) with a 30% yield.  
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    1       2 
Figure 1. Oxidation of the 5’ hydroxyl group of 1 to a carboxylic acid.  
2 was then purified using FPLC and characterized by matrix-assisted laser desorption-ionization 
time of flight mass spectrometry (MALDI-ToF-MS). Figure 2 shows a m/z of 2 of 1343.6 which is consistent 
with the expected m/z of [M-CN].  
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 Figure 2. MALDI-ToF MS of 2 expected [M-CN] 1344 m/z, observed 1343.6 m/z. 
2.2.1.2 Functionalizing B12 through addition of an alkyne via the carboxylic acid  
Following the synthesis of 2, a series of B12 molecules containing a terminal alkyne were 
synthesized. B12 was primed for click chemistry by coupling an alkyne-amine to the carboxylic acid of 2. 
Four B12-alkyne compounds (3-6) were synthesized with an alkyl chain containing a terminal alkyne varying 
from three to six carbons off of the carboxylic acid.13 Figure 3 shows the scheme used to synthesize the 
B12-alkyne compounds (3-6) utilizing 1-ethyl-3-(3-3-dimethylaminopropyl)carbodiimide (EDC) and 
hydroxybenzotriazole (HOBt). Successful conversion yielded compounds 2-5 with a yield of >90%.  
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 Figure 3. Synthesis of B12-alkyne precursors for B12-Ex-4. (i) EDCl, HOBt, propargyl amine, rt, DMSO, 16 h; 
(ii) EDCl, HOBt, 1-amino-3-butyne, rt, DMSO, 16 h; (iii) EDCl, HOBt, 1-amino-4-pentyne, rt, DMSO, 16 h; 
(iv) EDCl, HOBt, 1-amino-5-hexyne, rt, DMSO, 16 h; (v).  
 3-6 were successfully made and characterized through MALDI-ToF-MS as shown in Figure 4. 3 had 
an observed mass of [M-CN] 1381.7 m/z with an expected mass of 1382 m/z. 4 had an observed mass of 
[M-CN] 1393.6 m/z with an expected mass of 1394 m/z. 5 had an observed mass of [M-CN] 1407.7 m/z 
with an expected mass of 1408 m/z. 6 had an observed mass of [M-CN] 1421.9 m/z with an expected mass 
of 1422 m/z. 
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 Figure 4A. B12-propyne (3) MALDI-ToF MS expected [M-CN] 1380 m/z observed 1381.7 m/z. 
 
Figure 4B. B12-butyne (4) MALDI-ToF MS expected [M-CN] 1394 m/z observed 1393.6 m/z. 
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 Figure 4C. B12-pentyne (5) MALDI-ToF MS expected [M-CN] 1408 m/z observed 1407.7 m/z. 
 
Figure 4D. B12-hexyne (6) MALDI-ToF MS expected [M-CN] 1422 m/z observed 1421.9 m/z. 
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2.2.1.3 B12-Ex-4 conjugates (7-10) synthesized via CuAAC 
Compounds 2-5 were used to make a series of B12-Ex-4 conjugates with various linker lengths 
between B12 and Ex-4. B12 was conjugated to Ex-4 through Sharpless/Huisgen copper-catalyzed azide-
alkyne cycloaddition (CuAAC), click chemistry, utilizing copper(II) sulfate (CuSO4) and sodium 
ascorbate.14,15,16 Figure 5 shows the schematic for the synthesis of compounds 6-9.  
 
Figure 5. Synthesis of B12-conjugates 6-9. (v) 3, CuSO4, sodium ascorbate, Ex-4-K12-azido, Water/DMF 4:1, 
1 h; (vi) 4, CuSO4, sodium ascorbate, Ex-4-K12-azido, Water/DMF 4:1, 1 h; (vii) 4, CuSO4, sodium ascorbate, 
Ex-4-K12-azido, Water/DMF, 4:1, 1 h; (viii) 6, CuSO4, sodium ascorbate, Ex-4-K12-azido, Water/DMF; 1 h. 
>90% yield.  
2.3 In vitro optimization of B12-Ex-4 agonism at the GLP-1R 
The B12-Ex-4 series was first tested for function at the human GLP-1R in human embryonic kidney 
(HEK) cells, which had been stably transfected with the receptor. Activation of GLP-1R initiates the Gs 
cascade of the GPCR raising cAMP and PKA levels in the cell. This activity was monitored through a couple 
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of different assays using either a bioluminescence assay or FRET to follow the cascade resulting from 
activation of the GLP-1R. 
The first method used to follow GLP-1R agonism involved monitoring a FRET ratio change to follow 
PKA activity. To follow PKA levels HEK-GLP-1R cells are treated with adenovirus incorporating an A kinase 
activity reporter (AKAR3).17 AKAR3 is activated and a FRET change is seen upon phosphorylation by PKA 
(see Figure 2). This change in FRET is dose dependent and can be used to determine an EC50 for GLP-1R 
agonists.  
 
Figure 6. GLP-1R agonist induced GPCR Gs cascade resulting in AKAR3 activation by PKA. GLP-1R: glucagon-
like peptide-1 receptor; A.C.: adenylate cyclase; HEK-293: human embryonic kidney cells; ATP: Adenosine 
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triphosphate; cAMP: cyclic adenosine monophosphate; PKA: protein kinase A; YFP: yellow fluorescent 
protein; CFP: cyan fluorescent protein; FHA: forkhead associated; FRET: fluorescence resonance energy 
transfer.  
B12-Ex-4 activates the Gs pathway of the GPCR upon binding to GLP-1R. The Gs pathway activates 
adenylate cyclase (A.C.) which converts ATP to cAMP. As the cAMP level rises the enzyme PKA is activated 
and can then phosphorylate the threonine amino acid of AKAR3. This phosphorylation of AKAR3 results in 
a conformational change producing a decrease of 485/535 nm emission FRET ratio. This decrease in FRET 
ratio is dose dependent and can be followed to show EC50 values in vitro.  
Using AKAR3 to follow FRET ratio change allows for real time monitoring of changes. Figure 8 
shows the raw data in real time for a dose response series of 8. At t=100 s the injection of either saline or 
8 at a concentration between 10 pM and 10,000 pM was administered almost immediately resulting in an 
increase in PKA levels and change in FRET.  
 
Figure 7. Dose response of PKA phosphorylation of AKAR3 in real time after administration of either saline 
or 8 of concentrations ranging from 10-10,000 pM. 
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 7-10 were tested for agonism at the GLP-1R. The optimal conjugated Ex-4 would be used as the 
lead conjugate for further testing. Figure 9 shows the dose response results of each conjugate. The most 
potent conjugate, 8, had an EC50 of 68 pM followed by 7, 9, and 10, which had EC50’s of 121, 246 and 405 
pM, respectively compared to Ex-4 at 26 pM. Ex-4 has been shown to have an EC50 of 33 pM by Thorens 
et al. by following cAMP production so this method is consistent with previous literature reports.18   
 
Figure 8. Comparison of Ex-4, 7, 8, 9 and 10 EC50 curves with EC50 values of 27, 121, 68, 246 and 405 pM, 
respectively. 
8 was screened i as the optimal conjugate and was used for all further testing. Conjugation of B12 
to Ex-4 resulted in a relatively small loss of function and still maintained picomolar function at the GLP-
1R. Linker length played a small role in receptor agonism potency as EC50 of all of the conjugates were 
within one log unit, indicating that compounds 7-9 had essentially the same potency, of Ex-4 except for 
10. 
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2.3.1.1 B12-Ex-4 (8) affinity for B12 binding proteins 
After synthesis and optimization of the B12-Ex-4 conjugates and analysis of function at the GLP-
1R, binding affinities for the B12 binding proteins had to be confirmed. For B12 to be a viable oral delivery 
method modifications and conjugations have to be done in a way that won’t interfere with the ability of 
IF to recognize and bind the conjugate. TCII affinity is also important since it is responsible for delivery of 
B12 to cells. Binding of the conjugate to TCII could result in delivery to the CD320 receptor rather than the 
GLP-1R.   
IF and TCII binding of 8 was confirmed by radiometric chase assay using 57Co-labelled B12 and compared 
to free B12, as cyanocobalamin.19 IF and TCII binding of 8 (Kd values of 6.8 nM and 0.75 nM, respectively) 
was maintained, albeit reduced from unmodified B12 (0.12 nM and 0.098 nM respectively) see Figure 9. 
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Figure 9. TCII (A) and IF (B) binding of 8 compared to B12. 
After establishing binding to the B12 binding proteins 8 was tested for function at the GLP-1R while 
complexed to IF (see Figure 10). Since everywhere B12 is in the body it is bound to a binding protein, it is 
important to confirm that the conjugate could work while complexed to these B12 binding proteins. 
Picomolar agonism of GLP-1R is maintained even after IF complexation indication that 8 could work in the 
presence of these proteins.  
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Figure 10. Dose response curve of Ex-4, 8 and IF-8 yielding EC50s of 27, 68, and 132 pM respectively. 
  
The second method used for assaying GLP-1R agonism followed cAMP levels in the cell. HEK-293 cells 
stably expressing GLP-1R were first transfected with a rat insulin 1 promoter (RIP1) cAMP response 
element (CRE) encoding for the enzyme luciferase (Luc) (see Figure 11). The production of the enzyme 
luciferase is dependent on the cAMP levels after incubation with the GLP-1R agonist. Luciferin is then 
added to the cells and the amount catalyzed by luciferase can be determined through a bioluminescence 
readout. B12-Ex-4 and B12-Ex-4 complexed to the binding proteins IF and HC were tested for function and 
compared to Ex-4. Following cAMP through this RIP-CRE-Luc assay yielded an EC50 of 85 pM for Ex-4, 362 
pM for B12-Ex-4, 434 for IF-B12-Ex-4 and 426 for HC-B12-Ex-4. Both IF and HC showed similar effect on 
agonism at GLP-1R.  
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Figure 11. Ex-4, 8, IF-8 and HC-8 function at the GLP-1R monitored through RIP-CRE-Luc. 
2.4 In vivo testing of B12-Ex-4 (8) to demonstrate reduced brain uptake compared to Ex-4 
2.4.1 Glucose tolerance tests after B12-Ex-4 and Ex-4 administration 
Following the body’s response to a bolus of glucose is one of the oldest and most widely used 
tests to determine if a person is diabetic.20 A person with a normal response will show a blood glucose 
level below 140 mg/dL whereas a person with T2DM will reach a blood glucose level over 200 mg/dL.21 
There are two different ways to test for glucose tolerance, either with an oral bolus of glucose or an 
intraperitoneal bolus of glucose followed by an A1C1 reading of the blood at various time intervals.22,23 
Though in both instances the blood glucose levels rise, only through an oral bolus does the incretin effect 
occur. The body requires glucose to pass through the intestines for the appropriate receptors to be 
activated. This difference allows for determination of whether an incretin effect and intestinal stimulation 
is needed for our drug to elicit an effect.  
42
2.4.1.1 Oral glucose tolerance test of 8 compared to Ex-4 and saline 
An oral glucose tolerance test (OGTT) was performed on Sprague Dawley rats (n=12) (see Figure 
10) to compare the glucose controlling effects of 8 and Ex-4. For testing brain uptake of 8 and Ex-4 the rat 
model is a particularly effective since activation of the rat’s sympathetic nervous system (SNS) causes a 
characteristic rise in glucose level unlike the sharp decrease seen in mice and humans.24 Elimination of 
this glucose spike and an actual decrease in glucose points to a reduction of brain uptake with 8 versus 
Ex-4, which showed the normal increase in glucose. 
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Figure 12. Percent change in blood glucose (mg/dL) in Sprague Dawley rats (n=12) from baseline (t=-30) 
for vehicle, 0.9 nmol/kg Ex-4, 3.5 nmol/kg Ex-4, 0.9 nmol/kg 8, and 3.5 nmol/kg 8.  
2.4.2 Food Intake and Body Weight change with 8 administration 
A side effect associated with Ex-4 is weight loss, and though generally regarded as a positive it is 
unknown if the weight loss is a result of the nausea caused by Ex-4 or through some other process in the 
body.3 What is known though, is if GLP-1Rs in the brain are not activated the nausea and food intake 
reduction are not seen.25,26 If food intake reduction is mitigated, then brain activation of GLP-1Rs on the 
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AN are not activated. Figure 13 shows that administration of 8 at 0.2, 0.9 or 3.5 nmol/kg doses are 
ineffective at reducing food intake in rats (n=12).  
 
Figure 13. (Left) Food intake and (Right) body weight change over 24 h for either vehicle, 0.2 nmol/kg, 0.9 
nmol/kg, or 3.5 nmol/kg of 8 (vehicle, 0.2 nmol/kg, 0.9 nmol/kg, and 3.5 nmol/kg). 
Only at the two highest concentrations of 8 was there any change in food intake or body weight. 
Although this change was not significant the food intake and body weight study was repeated and 
compared to Ex-4 at a concentration of 0.9 nmol/kg (Figure 14 and Figure 15). Food intake reduction was 
significant for Ex-4 at 0.9 nmol/kg and significant for 8 but only at a concentration of 3.5 nmol/kg and with 
almost half the food intake reduction seen for Ex-4. Along with the reduction in food intake was a 
reduction in body weight. The largest average body weight reduction was from the Ex-4 treatment 
followed by 8 at 3.5 nmol/kg and then 8 at 0.9 nmol/kg.  
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 Figure 14. 24 h food intake comparison of Ex-4 at 0.9 nmol/kg to 8 at 0.9 nmol/kg and 3.5 nmol/kg. 
p=0.00012 for Ex-4 and p=0.023 for 8 at 3.5 nmol/kg when compared to baseline.  
 
Figure 15. 24 h body weight comparison of Ex-4 at 0.9 nmol/kg to 8 at 0.9 nmol/kg and 3.5 nmol/kg. 
p≤0.05 
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2.4.3 PICA studies establishing nausea levels for 8 vs. Ex-4 
Measuring nausea in rats as a response to Ex-4 can be done by looking at the way the rats behave. 
Rats are particularly good model to study nausea on since they are unable to vomit and behave in a 
predictable way when experiencing nausea.27 There are a couple of tests that can be used to measure 
nausea. The first test is conditioned taste aversion and the second is pica, which is when the rat consumes 
a nonnutritive food such as kaolin,.28,29   
A pica test was used to follow the level of nausea in the rats by following kaolin consumption. 
Kaolin intake was followed over 24 hours after administration of 0.9 nmol/kg of Ex-4, 0.9 nmol/kg of 8, or 
3.5 nmol/kg of 8 (see Figure 14). Ex-4 treatment was the only instance of significant increase in kaolin 
intake when compared to baseline. Concentrations of 8 up to 4x that of Ex-4 still trended to lower nausea 
as indicated by the reduced kaolin intake. This study is still on-going to increase statistical significance 
prior to publication (To be submitted to the journal ‘Diabetes (IF 12)’ with this author as ‘first author’).   
 
Figure 16. 24 h kaolin intake after Ex-4 at 0.9 nmol/kg and 8 at 0.9 nmol/kg and 3.5 nmol/kg administration 
(n=6). 
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2.5 Outcomes and conclusions 
The in vitro assays show that 8 and the complex IF-8 maintain picomolar agonism at the GLP-1R and 
are both within one log order of the Ex-4 EC50, whether following cAMP directly or indirectly through PKA 
levels. The modifications to Ex-4 do not significantly change the agonism at the receptor, and the 
conjugation still allows for binding to the B12 binding proteins. In vivo results reveal that the changes to 
the hydrophilicity have changed the pharmacodynamics of Ex-4. The conjugation to B12 reverses the 
hyperglycemia seen in rats and works to lower the glucose levels. The most significant finding of this 
chapter is that B12 conjugation to Ex-4 shows a smaller decrease of food intake and reduction of nausea. 
This suggests a blocking of central GLP-1R activation, presumably in the brain, while allowing peripheral 
GLP-1R activation to produce glucoregulation responses from the pancreas to continue. This work has 
considerable potential to be a new form of the Ex-4 pharmaceutical without the side-effect of chronic 
nausea. The goal of this chapter, to remove side-effects of Ex-4 without loss of glucoregulation, was 
achieved in a rat model. 
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Chapter 3: IF protection of 8 from systemic and pancreatic proteases 
Work in this chapter resulted in the publication of: Bonaccorso, R. L.; Chepurny, O. G.; Becker-Pauly, C.; 
Holz, G. G.; Doyle, R. P., Enhanced Peptide Stability Against Protease Digestion Induced by Intrinsic Factor 
Binding of a Vitamin B12 Conjugate of Exendin-4. Molecular Pharmaceutics 2015, 12 (9), 3502-3506. 
3.1 Introduction 
The future of pharmaceutics and medicinal chemistry is in peptide therapeutics. Peptides in general 
offer several advantages over small molecule drugs, which have historically dominated pharmaceutical 
research and therapeutics, including fewer side effects, greater selectivity, and higher potency.1 Because 
of the high selectivity possible with peptides, new therapeutics can be used to target difficult to treat 
diseases.2  Peptide drug research is still relatively new, but it is a quickly growing field of pharmaceutical 
research.3  
Despite the many benefits of peptide therapeutics, there are several major hurdles facing peptide 
therapeutics, including rapid degradation through proteolysis, short half-lives and rapid clearance, and 
low oral bioavailability.4 One of the many benefits of peptides as therapeutics is increased potency. 
Unfortunately, without an increase in half-life these peptides offer limited therapeutic value even with 
their higher potency. One such example of this is GLP-1, which, despite its potency, offers no therapeutic 
value due to its short half-life.5 In vivo half-life has been increased through use of albumin and 
pegylation.6,7 To increase the pharmaceutical potential of peptide research an effective and easily 
employable method of increasing oral bioavailability and protease resistance is essential.8  
Extensive research into increasing oral bioavailability and peptide stability has led to promising results 
and several drugs using these new methodologies are in clinical trials.9 There is still no “go to” technique 
to provide oral delivery and protease resistance.10 Many of these techniques alter the potency and 
inactivate the drug. This underlies the reason to have multiple methodologies and techniques to use for 
peptide delivery and proteolysis resistance.   
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Most approved peptide medications are taken through injection.11 The low oral bioavailability of these 
peptides is due to their potential for degradation by enzymes and proteases.12 Ex-4, although resistant to 
degradation in the blood and currently available as a therapeutic, is an example of an injectable peptide 
prone to degradation by pancreatic proteases.13 In attempts to prevent degradation, Ex-4 can be used as 
a probe to detect proteolysis by following GLP-1R agonism after digestion. The level of maintained 
agonism at the receptor should correlate inversely with the amount of peptide digested.  
In chapter 2 I demonstrated that IF binding of B12, upon conjugation to Ex-4, was maintained. It was 
also demonstrated that functional agonism of GLP-1R was maintained with low picomolar agonism. The 
question targeted herein is whether IF binding of 8 to a dietary uptake protein can offer protection to the 
conjugated peptide as well as the B12 molecule.14 B12 is a particularly attractive candidate for peptide 
conjugation since it possesses no inherent negative side effect.15  The hypothesis is that upon 
complexation IF should shield 8 from proteases thereby protecting it from degradation. IF’s natural 
resistance to proteolysis and encapsulation of B12 make it an ideal shield for degradation of conjugates as 
well.16,17 To test this hypothesis 8 and IF-8 need to be incubated in the presence of proteases and then 
tested for agonism at the GLP-1R.  Stability of Ex-4, 8 and IF-8 against the abundant intestinal 
endopeptidases, which represent both gastric and systemic proteases (see Table 1), trypsin, 
chymotrypsin, and meprin β were compared by measuring relative function at the GLP-1R after 
digestion.18,19,20 This work will test the value of IF in protecting B12 from proteases. This work will show the 
potential of IF and B12 conjugation and possibly provide evidence for oral delivery of therapeutics through 
the B12 dietary pathway.  
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Table 1. Proteases and where they cut 
 
Trypsin Chymotrypsin Meprin β 
Designation Basic Aromatic Acidic 
Location Gastric Gastric Systemic 
Digestion Locations Lysine and Arginine 
Tyrosine, Tryptophan 
and Phenylalanine 
Aspartic acid, Glutamic 
acid 
3.2 In vitro testing of IF protection of 8  
Ex-4, 8 and IF-8 were analyzed for stability against proteases by measuring remaining function at the 
receptor compared to undigested controls.  Ex-4, 8 and IF-8 were tested for function at [100 nM], a 
concentration at which each had comparable percent change in FRET ratio (see Table 1). After establishing 
a reference point for 100% function each sample could be tested for agonism relative to 100% function 
after proteolysis.  
Table 2. % Change in FRET at 100 nM for Ex-4, 8 and IF-8.  
Compound % Change in FRET 
at 100 nM 
Ex-4 -12± 0.01 
8 -13± 0.02 
IF-8 -12± 0.01 
 
Digestion was conducted in a standard extracellular solution containing either trypsin at 11, 22, or 50 
μg/mL, chymotrypsin at 1.25, 3, or 6.25 μg/mL or meprin β at 2 or 10 μg/mL see Figure 1 and Figure 2. 
Three different concentrations of the pancreatic proteases were used to track the relative differences 
between 8 and IF-8 (see Figure 1). At the lowest concentration of trypsin (11 μg/mL) and chymotrypsin 
(1.25 μg/mL) there is up to 50% greater function for IF-8 relative to 8 alone with the highest concentration 
of trypsin (50 μg/mL) and chymotrypsin (6.25 μg/mL) assayed showing complete lack of function for all 
systems. The digestion was monitored by measuring agonism of the drugs at the GLP-1R, initially over the 
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course of 3 h, although it was quickly noted that there was no change after 1.5 h indicating that the 
digestion had stopped by this time point (data not shown). Subsequent triplicate runs were then 
performed on digestions of 1.5 h. 
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Figure 1. Top: column graph and Bottom: scatter plot of 1.5 h trypsin and chymotrypsin digestion of 100 
nM Ex-4, 8 and IF-8 with 50, 22 or 11 µg/mL of trypsin or 1.25, 3, or 6.25 μg/mL of chymotrypsin using 
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AKAR3 to measure function. The data shows the maximum expression normalized to 100% of the 
conjugates done in triplicate (mean ± SEM). Basal control contained trypsin at 50 μg/mL of trypsin. (N.C. 
= no change). 
Meprin β digestion revealed a 3.3 fold increase in function with B12 conjugation and a 4.5 fold increase 
in function when pre-bound to IF (see Figure 5). No function was seen for Ex-4 at concentrations greater 
than 3 μg/mL. The protection provided from B12 conjugation and subsequent binding to IF show that key 
residues are being protected. Results of the AKAR3 assays show maintenance of function where otherwise 
none was observed or improvement of function when 4 is first bound to IF. B12 conjugation itself offered 
some protection at the low trypsin concentrations tested. 
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Figure 2. Left: column graph and Right: scatter plot of 30 min meprin β digestion of 100 nM Ex-4, 8 and 
IF-8 with 2 and 10 µg/mL of meprin β. The data shows the maximum expression normalized to 100% of 
the conjugates done in triplicate (mean ± SEM). Basal control contained 2 µg/mL of meprin β. 
Recombinant human meprin β was produced in insect cells and purified and activated as described 
previously. 
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3.3 Outcomes and conclusions 
The conservation or improved relative function demonstrated herein for Ex-4 when conjugated to B12 
and more significantly, when bound by IF is an important first-step in addressing the use, and putative 
role, of IF in delivering and protecting an orally administered peptide. Protection against pancreatic 
protease-catalyzed hydrolytic digestion of 8 was maximal at an optimal trypsin concentration of 22 μg 
/mL of trypsin and 3 μg/mL of chymotrypsin when 8 was pre-bound to IF, providing a 4-fold and 7.5-fold 
positive increase in function respectively as measured by GLP-1R agonism (utilizing a new AKAR3 
screening assay). The digestion with metalloendoprotease meprin β showed the most significant 
protection when comparing Ex-4 and IF-8. No reduction in function was seen at the highest concentration 
of meprin β while 1 showed no function at concentrations greater than 2 μg/mL of meprin β. B12 provided 
some protection against trypsin relative to the native peptide. The effect is seen at 11 μg/mL of trypsin 
with a relative increase of 3-fold and at 1.25 and 3 μg/mL of chymotrypsin with a relative increase of 3 
and 1.6-fold. The fact that the IF bound form IF-8 still maintained significant function at the GLP-1R is also 
highly significant since many routes to protect against intestinal degradation involve encapsulation, which 
prevents possible luminal function or absorption when in place. The use of IF to improve the protease 
stability of a peptide offers significant scope for exploitation. Even a small improvement in oral function 
may be sufficient to achieve the targeted effect. Combining this approach with a highly potent peptide 
with known gut receptors that can produce a vagal afferent response (such as, but not limited to, GLP-
1/Ex-4 or PYY(3-36)) for example, may allow for a positive clinical outcome to be achieved orally, without 
need even for systemic delivery. Finally, as demonstrated by the stability against meprin β, there is no 
suggestion that this approach is limited to use against gastric proteases, but could also be expanded into 
serum (through intravenous injection of IF bound peptide conjugates for instance), facilitating greatly 
improved pharmacokinetics, making this a possible platform technology for peptide drug delivery. The 
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goal of this chapter, to test that IF binding of 8 confers protection against gastric proteolysis as a road map 
to oral peptide delivery.  
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Chapter 4: Rationally designed GLP-1R/Y2R agonist peptide 
The work in this chapter was done in collaboration with Professor George G. Holz and Dr. Christian L. Roth. 
The work reported in this chapter will be submitted to PNAS with the title “Diabetes and weight loss 
therapy through hybrid peptides” and coauthors: Ron L. Bonaccorso, Clinton L. Elfers, George G. Holz, 
Christian L. Roth and Robert P. Doyle 
The work from this chapter resulted in a patent pending: SU100846_156P471  
 
4.1 Introduction 
Weight loss research has been given a lot of attention in recent years due to the growing epidemic of 
obesity.1 Despite all of the research and therapeutic options, effective weight loss treatments have been 
difficult to find.2 There are only five FDA approved drugs marketed for treatment of obesity but the 
effectiveness of these drugs are variable and not consistent from patient to patient.3 Several diabetes 
medications have been shown to cause weight loss and recently liraglutide has even been approved as a 
weight loss medication.4 Most of these drugs show limited effectiveness, and many potential drugs either 
lose effectiveness over time or result in significant weight gain after treatment has ended.5 The body is 
able to invoke a counter-regulatory response and ignore the signals suppressing appetite deeming the 
drug ineffective.6 
Studies have shown that combination therapy can be effective at treating obesity.7 Drug cocktails 
however are difficult and expensive to test since there are multiple PK and PD pathways to test and side 
effects to consider. A single peptide that targets multiple receptors is an ideal candidate to treat obesity.8 
Combination treatments consisting of GLP-1R agonists and NPY2R agonists have shown to be particularly 
effective at treating both diabetes and obesity.8 Coagonism of GLP-1R and either the glucagon receptor 
(GCGR) or GIPR have shown to have enhanced glucose and weight loss control as well.9,10 Current co-
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agonists have shown to be effective in vitro but have limited efficacy in vivo. T2DM and obesity 
management through combination therapies have potential to be effective and are expected to be the 
future of weight control therapeutics.11 
4.2 Design of hybrid proteins 
To overcome the compensatory effects of PYY(3-36), a hybrid peptide, made from fragments of Ex-4 
and PYY(3-36), should be able to target both GLP-1R and NPY2R without the PD effects of two different 
drugs. A series of peptides were designed with the goal of combining fragments of Ex-4, which were vital 
for GLP-1R agonism, and fragments of PYY(3-36), which are necessary for maintaining agonism to the 
NPY2R.12 The similarity between glucagon receptor superfamily peptides opens the possibility of receptor 
agonism at GIPR and GCGR.13,14 An initial series of three sequences were designed with the first two 
peptides composed primarily of Ex-4 sequence and the third as a modified version of PYY(3-36). Table 1 
shows the comparison of each peptide in relation to Ex-4 and PYY.  An initial series of 3 peptides, RLB001 
(11), RLB002 (12) and RLB003 (13), was designed to screen for dual agonism. After the results of these 
three peptides an additional three, RLB004 (14), RLB005 (15) and RLB006 (16), were designed. The last 
three peptides were designed to try and improve upon the initial series of 11, 12 and 13 to produce an 
effective dual or even triagonist.15   
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Table 1. Hybrid peptide design and comparison. Sequences corresponding to 11-16 were designed with 
elements of PYY(3-36) and Ex-4. Amino acid sequence taken from PYY(3-36) is shown in blue and amino 
acid sequence taken from Ex-4 is shown in black.   
 
4.3 In vitro screening and testing 
The RLB series peptides were tested for function at receptors corresponding to the glucagon super 
family of receptors and NPY receptors. These receptors were transfected into either HEK293 cells or CHO 
cells. HEK 293 cells stably transfected with either GLP-1R or GIPR followed by an infection of adenovirus 
incorporating AKAR3 to indirectly follow cAMP production. CHO cells were transfected with NPY2R and a 
promiscuous g protein using FURA2 to follow calcium release.  
4.3.1 Screening the RLB series for GLP-1R agonism and dose response 
Function was first established at the GLP-1R by screening the initial conjugates in the HEK-GLP-1R 
cells. These cells were treated with adenovirus containing AKAR3 and a agonism was determined by a 
decrease in FRET ratio. The initial screen of compounds is found in Figure 1 and shows that 11, 12 and 14 
have agonism at the GLP-1R. 13 showed no function at the GLP-1R at 300 nM making ineffective as a GLP-
1R and NPY2R coagonist. 
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 Figure 1. A screen of RLB series peptides at the GLP-1R at 300 nM. 
The initial screen showed that modifications to Ex-4 don’t completely hinder function at the GLP-
1R.  The peptides showing function at the GLP-1R were then analyzed further to establish an EC50. Figure 
2 shows that 11 and 14 are the most effective with EC50 values of 50 ± 3 pM and 128 ± 30 pM, respectively 
and followed by 12 at 253 ± 50 pM.  
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Figure 2. Dose response comparison of 11, 12 and 14 to Ex-4. 12 has a p-value of 0.0032 compared to Ex-
4 and 11. 
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11, 12 and 14 all retained picomolar agonism at GLP-1R warranting further analysis at NPY2R and 
other glucagon superfamily receptors. 13 was discarded as a potential dual agonist due to its loss of 
function.  
4.3.2 Screening the RLB series for NPY2R agonism and dose response 
Following a screen at the GLP-1R, a screen for agonism at NPY2R was conducted. Figure 4 shows 
full function was only achieved with 12 and 14. Positive results show that a successful in vitro dual agonist 
of GLP-1R and NPY2R was achieved.  
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Figure 3.  NPY2R screen with RLB series of peptides at [300 nM].  
12 and 14 were followed up with a full dose response curve to establish an EC50 for each peptide 
(see Figure 4). PYY(3-36) was used as the positive control to show that each peptide shows comparable 
agonism at the NPY2R through in vitro trials. 14 had an EC50 of 107 ± 9 nM and 12 had an EC50 of 59 nM.  
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Figure 4. NPY2R EC50s of 12, 59 nM, and 14, 107 nM. 
4.3.3 Screening the RLB series for GIPR and GCGR agonism and dose response 
After establishing agonism at the GLP-1R, the RLB series peptides were tested against similar 
receptors. Receptors in the glucagon receptor superfamily were tested based on the similarities of native 
peptide agonists. Shown in Figure 5 are the results of the GIPR screen, where only 11 and 15 showed 
function at the GIPR and Ex-4, PYY, 12 and 14 showed no function under 1 µM.   
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Figure 5. GIPR dose response and EC50 values of 11 (275 nM) and 15 (173 nM). Note: Ex-4, 12, 14 and PYY 
were all tested with no agonism up to 1 µM. 
Peptides 11 and 14 were screened for GCGR agonism compared to Ex-4. Each of these peptides, 
including Ex-4, showed slight agonism at the receptor at high concentrations (>300 nM). Only peptides 
11, 12 and 14 were confirmed to have function at more than one receptor. 11 is an effective in vitro dual 
agonist of GLP-1R and GIPR and 12 and 14 are effective agonists of GLP-1R and NPY2R. 
4.4 In vivo testing of 11 compared to Ex-4 and PYY(3-36) 
After the initial screening of the RLB series peptides an in vivo study was planned to compare the dual 
agonists 11 and 14 to Ex-4 and PYY(3-36). Since 12 was significantly less potent at the GLP-1R it was not 
selected for in vivo testing. A one-day food intake screen of 11 and 14 showed that 11 had a reduction in 
food intake but 14 actually resulted in the opposite effect and caused an increased food intake from the 
rats (see Figure 6). Given the initial results only 11 was pursued. 
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Figure 6.  Initial screen of food intake for compounds 11 and 14 at 2.4 nmol/kg over 16 h. 
11 was isolated as the lead candidate for both blood glucose control and weight loss. A dose 
response study in was then completed in rats to determine the optimal concentration of 11. A two day 
food intake study was conducted to verify that 11 behaved uniquely when compared to Ex-4 and co-
administration of Ex-4 and PYY(3-36). Figure 7 shows the results of a two day food intake study comparing 
11, Ex-4 and a mixture of Ex-4 and PYY(3-36) all at 2.4 nmol/kg per day. The total reduction of food intake 
for all three samples is shown in Figure 8. 11 shows a significant improvement over Ex-4 alone and an 
average lower food intake when compared to Ex-4 and PYY(3-36) co-administration. This establishes that 
11 is not Ex-4 but rather a new and different drug. 
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 Figure 7. Inhibition of food intake of 11 compared to Ex-4 and Ex-4 and PYY(3-36) combined each at 2.4 
nmol/kg/d.  
 
Figure 8. Normalized food intake against baseline levels for 11, Ex-4 and Ex-4 and PYY(3-36) shown over 
12 and 23 h.  
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Food intake was studied further in diet induced obese (DIO) rats over two days comparing 11’s treatment 
at 2.4 nmol/kg to an equimolar mixture of Ex-4 and PYY(3-36) at 2.4 nmol/kg (shown in Figure 9). In each 
category 11 is out performing Ex-4 and PYY(3-36) combination treatments.  
 
Figure 9. On the left is shown food intake over a two day study with DIO rats administered either 2.4 
nmol/kg of 11 or an equimolar mixture of Ex-4 and PYY(3-36). On the right is shown the change in body 
weight gain of the 11 treatment vs the equimolar Ex-4 and PYY(3-36). 
 
Figure 10. Food intake comparison for 11 and Ex-4 at 10 nmol/kg/d over two days normalized to 
pretreatment baseline in young 9 week old rats (3 males and 2 females per group). 
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Direct comparison of 11 and Ex-4 at 10 nmol/kg dosing is seen in Figure 10. 11 is able to provide an 
average decrease in food intake lower than Ex-4 at both 12 h and 23 h time points.  
4.5 Glucoregulatory effects of 11 versus Ex-4 
11 was compared directly to Ex-4 to determine efficacy in blood glucose control. An intraperitoneal 
glucose tolerance test was performed on rats to treated with 11, Ex-4 and saline (see Figure 11). Both Ex-
4 and 11 showed a similar prolonged increase in glucose levels characteristic of Ex-4 in rats. This indicates 
that the mechanism of action for 11 to control glucose is the same as Ex-4. 
 
Figure 11. (Left) Blood glucose levels after administration of saline, 11 and Ex-4 following a 10 day 
treatment (10 nmol/kg/d, 2 males and 2 females per group). (Right) Fasting glucose level reduction after 
a two day treatment with 10 nmol/kg/d 11 in 31-wk old male rats.  
4.6 Outcomes and conclusions 
A summary of the results from the in vitro agonism of each receptor is highlighted in table 2. In vitro 
results were able to confirm dual agonist function with 11 at the GLP-1R and GIPR and dual agonist 
function with peptides 12 and 14 at the GLP-1R and NPY2R. 11 and 14 were the most potent GLP-1R 
agonist in vitro and were initially chosen for in vivo trials. No peptide showed any significant function at 
the NPY1R or the glucagon receptor.  
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Table 2. Summary of receptor agonism results. (NT= Not tested, *11 and 14 saw no change in EC50 after 
3 months in solution, **B12-16 was tested in place of 16. 
 
The in vivo results showed that 14 had the reverse effect on appetite and weight loss and caused an 
increase in both. 11 despite no NPY2R agonism in vitro showed improved efficacy at reducing weight gain 
and suppressing appetite. 11 even showed improved function over combination therapy of Ex-4 and 
PYY(3-36) at equimolar dosing at controlling food intake and weight reduction. 11 and Ex-4 showed similar 
profiles in their glucoregulatory abilities though. 11, although similar in glucose control, possesses an 
enhanced ability to control appetite and promote weight loss. There is a need for effective treatment of 
obesity and T2DM and the initial testing of 11 shows that it there is great potential for it as a lead drug 
candidate. The goal of this chapter was to create a new lead therapeutic that simultaneously treats 
diabetes and obesity and this was accomplished.  
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Chapter 5: Experimental 
5.1 Materials and Methods 
The chemicals and solvents were purchased from Sigma-Aldrich, VWR, or Thermo Fisher Scientific and 
used without further purification. Cyanocobalamin (B12), 2-iodoxybenzoic acid (IBX), 2-hydroxypyridine 
(HYP), dimethyl sulfoxide (DMSO), propargyl amine, 1-amino-3-butyne, 1-amino-4-pentyne, 1-amino-5-
hexyne, 1,1’-carbonyldi(1,2,4-triazole), trimethylamine (TEA), carbodiimide, hydroxybenzotriazole 
(HOBt), dimethyl formamide (DMF), copper(II) sulfate (CuSO4) sodium ascorbate, and α-cyano-4-
hydroxycinnamic acid (CHCA) were purchased from Sigma Aldrich. Black costar plates with a clear bottom 
were purchased from Thermo Fisher Scientific. PYY(3-36) K4-azido, PYY(1-36), Ex-4 K12-azido, 11, 12 and 
13 were purchased from C.S. Bio Lab (Cambridge, MA). 14, 15, 16 and 14 azido were all purchased from 
NeoBiolab (Cambridge, MA). H2O was distilled and deionized using an 18.2 mΩ Barnstead Nano Diamond 
ultra-purification system. Fetal bovine serum (FBS), PenStrep, Dulbecco’s modified eagle media (DMEM), 
F-12K, Pluronic F-127 and Fura-2 acetoxymethyl ester (Fura-2AM) were purchased from Invitrogen Life 
Technologies, Carlsbad, CA. Acetonitrile, methanol and tetraflouro acetic acid (TFA) were purchased from 
VWR. In vitro plate assays were completed using a Molecular Devices FlexStation III running SoftMaxPro 
software.  Xeragenix supplied the human intrinsic factor, which was expressed in Arabidopsis thaliana.  
RP-HPLC was performed using either an Agilent 1100 system or a Shimadzu Prominence with an 
Agilent Eclipse C18 XBD analytical column (5 µm x 4.6mm x 150 mm). Fast protein liquid chromatography 
(FPLC) was performed using an AKTAprime plus (GE Healthcare) liquid chromatograph with an automated 
fraction collector and 5 mL diethyleaminoethyl (DEAE) anion-exchange (AE) column.  
MALDI-ToF MS was performed on a Bruker Autoflex III Smartbeam with a laser intensity between 10-
20% for samples smaller than 2,000 Da (B12 precursor compounds) and between 40-50% for samples larger 
than 2,000 Da (peptides and bioconjugates). A CHCA matrix was used for all samples and was prepared by 
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dissolving 10 mg of CHCA to a 50:50 mixture of water and acetonitrile containing 0.1% TFA. Samples were 
then analyzed by MALDI-ToF-MS using a 50:50 mixture of sample to matrix.  
5.2 B12-Ex-4 Synthesis 
5.2.1 Synthesis of B12-Carboxylic Acid 
1 (1 equivalent), IBX (2.5 equivalents) and HYP (5 equivalents) were dissolved in DMSO at 60 0C 
for 3 h. The reaction was then precipitated out using 15:1 diethyl ether and acetone. The crude reaction 
was then dissolved in H2O and purified by FPLC using 100% water to bind 2 to the DEAE AE column and 
2% NaCl in water to elute pure 2.  
5.2.2 Synthesis of B12-Alkyne Compounds (3-6) 
2 was combined with 10 equivalents of EDCl and 20 equivalents of HOBt in dry DMSO under argon 
and stirred for 20 minutes. To this reaction 10 equivalents of 1-amino-3-butyne was added. This reaction 
proceeded for 16 h and was then precipitated out with the addition of acetone and ether at a 4:9 ratio.  
This reaction was separated by HPLC with a flow rate of 1 mL/min and a 1 mL/min gradient of 0-13% 
acetonitrile over 13 minutes with a retention time of 5 min. 
5.2.3 Synthesis of B12-Ex-4 compounds (7-10) 
Ex-4 was then conjugated to 2 using copper-catalyzed alkyne-azide cycloaddition.1 This 
conjugation was achieved by dissolving Ex-4-K12-azido with either 3, 4, 5, or 6 in a 1:3 ratio, respectively 
with copper(II) sulfate (CuSO4) and sodium ascorbate in water/DMF (4:1) and stirring for 1 h.  The reaction 
yields were greater than 90% with isolated purity greater than 95% for 6-9 as indicated by HPLC in all cases  
6-9 were separated from Ex-4 and unreacted 1 on a C18 column (see Figure 3) monitored at both 280 
and 360nm. A mobile phase of 0.1% TFA water was used with a flow rate of 1 mL/min and a gradient from 
20-42.5% acetonitrile for 3 min then 42.5-47% acetonitrile for 12 min. Isolated conjugates 6-9 were 
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confirmed by electrospray mass spectrometry. The bioconjugates were separated as two peaks due to the 
aggregation of Ex-4.  
5.3 In vitro work following agonism at GLP-1R, GIPR, NPY2R and NPY1R 
5.3.1 GLP-1R agonism 
HEK-293 cells stably transfected with human GLP-1R (HEK-GLP-1R) were used to test for agonism of 
each peptide and peptide conjugate. The HEK-GLP-1R cells were grown in DMEM with 10% fetal bovine 
serum (FBS), 1% pen-strep and 0.1% geneticin all produced by Gibco.  Cells were incubated at 37 oC in a 
humidified incubator with 5% CO2. Cells were plated at 60,000 cells per well on a 96 well plate coated with 
rat tail collagen and incubated for 24 h. To follow protein kinase A activity media was removed from the 
cells and DMEM containing 1% FBS and adenovirus incorporating the A-kinase activity reporter 3 (AKAR3) 
with a multiplicity of infection per cell of 25 was added to each well.2 After 20 h of incubation the media 
was removed and 200 µL of standard extracellular solution (SES) was added to each well. Another 50 µL 
of SES containing conjugate was added to each well and immediately measured at 485 and 535 nm upon 
excitation at 440 nm.  To follow cAMP production media was removed from the cells and DMEM 
containing RIP-CRE-Luc (200 ng/well), Lipofectamine, and Plus reagent was added to each well. Cells were 
incubated for 3 h and then an additional 200 µL of DMEM with 10% fetal bovine serum and 1% penstrep 
was added. After 36 of incubation the media was removed and 100 µL of DMEM with 0.1% bovine serum 
albumin containing the conjugate to be tested was added to each well and incubated for an additional 4 
h. Cells were then lysed from the plate and tested for luciferase activity by measuring photoemissions.   
5.3.2 GIPR agonism 
HEK-293 cells stably transfected with human GIPR (HEK-GIPR) were used to test for agonism of 11, 12, 
14, and 15. The HEK-GIPR cells were grown in DMEM with 10% fetal bovine serum (FBS), 1% pen-strep 
and 0.1% geneticin all produced by Gibco.  Cells were incubated at 37 oC in a humidified incubator with 
74
5% CO2. Cells were plated at 60,000 cells per well on a 96 well plate coated with rat tail collagen and 
incubated for 24 h. To follow protein kinase A activity media was removed from the cells and DMEM 
containing 1% FBS and adenovirus incorporating the A-kinase activity reporter 3 (AKAR3) with a 
multiplicity of infection per cell of 25 was added to each well. After 20 h of incubation the media was 
removed and 200 µL of standard extracellular solution (SES) was added to each well. Another 50 µL of SES 
containing conjugate was added to each well and immediately measured at 485 and 535 nm upon 
excitation at 440 nm.   
5.3.3 NPY1R and NPY2R agonism 
CHO cells were used to test for agonism of each peptide and peptide conjugate. The CHO cells were 
grown in F12K media with 10% fetal bovine serum (FBS) and 1% pen-strep.  Cells were incubated at 37 oC 
in a humidified incubator with 5% CO2. Cells were plated at 20,000 cells per well on a 96 well plate coated 
with rat tail collagen and incubated for 24 h. To follow NPY2R or NPY1R activation, media was removed 
from the cells and F-12k containing either NPY2R or NPY1R (20 ng/well), Lipofectamine, and Plus reagent 
was added to each well. Cells were incubated for 3 h and an additional 200 µL of DMEM with 10% fetal 
bovine serum and 1% penstrep was added. After 36 of incubation the media was removed and 100 µL of 
SES containing Fura-2 AM and pluranic acid F-127 were added to the cells to follow Ca2+ production and 
incubated for 30 min. The SES mixture was removed and 150 µL of SES was added to each well. Another 
50 µL of SES containing conjugate was added to each well and excited at both 355/9 nm and 375/9 nm.  
Upon Fura-2 coordination with Ca2+ 505 nm light was emitted.    
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5.4 In vivo studies following glucoregulation and food intake after 8 and 11 administrations in Sprague 
Dawley rats 
In vivo studies on 8 were done in collaboration with the Hayes lab at UPenn, and in vivo studies on 11 
were done in collaboration with the Roth lab at Seattle Children’s Research Institute. In vivo studies are 
still ongoing for both 8 and 11.  
5.5 Glucoregulation Studies 
Either saline, Ex-4 or 8 was administered at t=-30 min followed by an oral bolus of glucose at t=0 min. 
Blood glucose levels were monitored at t=-30, 0, 30, 60, and 120 min. Either saline, Ex-4 or 11 was 
administered at t=-30 min followed by an oral bolus of glucose at t=0 min. Blood glucose levels were 
monitored at t=-30, 0,5,15, 30, 60, and 120 min. 
5.6 Food intake and body weight 
Food intake was monitored using a metabolic cage. Food was removed from the rats during the last 
hour of the light cycle while the rats were weighed.  
5.7 Pica study upon treatment with saline, Ex-4 or 8 
Sprague Dawley rats were administered treatment and left alone in cages with both kaolin and chow 
present. Total kaolin consumption was measured after 24 h. A high consumption of kaolin is indicative of 
nausea.  
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6 Future Work 
6.1 Retest pica and perform conditioned taste aversion testing on rats administered 8 
The pica study on rats after administration of 8 will be expended on to include a larger sample size 
and more accurate error bars. The rats will be administered either saline, Ex-4 or 8 and then exposed to 
kaolin again. Consumption of kaolin will be calculated and compared to baseline to determine relative 
levels of nausea caused by each treatment. 
Nausea will also be measured through conditioned taste aversion (CTA). The rats will first be place 
under water depravation for one week and be allowed water for only a limited amount of time a day. 
After a week rats were given a flavored water solution during the period of water access. Right after the 
flavored water is taken away the rats are administered either vehicle or drug. This is done for a couple of 
days followed by resting period. Rats are then given a choice of flavored water and the position of the 
flavored waters is switched half way through the water period. A preference for the new flavor indicates 
CTA.1 
6.2 Test for IF-8 protection against IF degrading proteases 
IF-8 will be screen against more proteases. Cathepsin L is known to degrade IF so the question that 
will be answered is whether IF will continue to protect B12 and 8 in the presence of cathepsin L.2 I have 
shown that IF protects 8 from degradation relative to unbound controls in an environment where IF is 
resistant to the only proteases present. Upon internalization into the ileum IF is degraded by lysosomal 
protease cathepsin L. Will this environment also damage 8 or will IF offer enough protection to allow a 
high enough percentage of 8 to enter the blood stream intact.  
The first part of this experiment will involve running control to determine if 8 is digested by cathepsin 
L. Once the level of degradation is known, a protease cocktail will be used to degrade IF-8. The protease 
mixture will first contain proteases used in the previously published work such as trypsin, chymotrypsin 
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and meprin β. Additional proteases will need to be tested especially other cathepsins. After establishing 
the robustness of IF-8 protection other B12-peptide conjugates will be tested for stability. Establishing IF 
binding as a way to improve protease resistance for a drug will open IF and B12 conjugation to investigation 
as a potentially new oral delivery technique. 
6.3 Continue in vitro and in vivo testing on 11  
6.3.1 Screen for activity at NPY1R and NPY2R following the native Gi pathway 
An assay has been developed to follow the Gi pathway in NPY2R agonism. The current assay 
however does not produce a strong enough response to report an accurate dose response curve. HEK-
293 cells endogenously express the adenosine receptor, which upon agonism causes an increase in cAMP 
levels.3 A two injection system was used in preliminary data to first stimulate cAMP production through 
the Gs pathway, with an adenosine injection, and the second injection was used to shut down cAMP 
production through the Gi pathway using PYY(3-36).  Figure 1 shows the ability of PYY(3-36) to lower cAMP 
levels and prevent FRET ratio from decreasing further.  
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Figure 1. Adenosine induced cAMP rise to show PYY(3-360’s ability to work through the Gi pathway and 
lower cAMP levels.  
The raw data is shown as a ratio of 485/535 emission. The total reduction in is calculated by taking 
the total average FRET ratio change between 360 s and 420 s to determine the relative effectiveness of 
raising and lowering the cAMP and PKA levels.    
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 Figure 2. FRET ratio change in real time over 420s after a first injection of adenosine at 100 s followed by 
PYY(3-36) at 140 s.  
Although the current assay to show native Gi pathway activation after NPY1R and NPY2R agonism does 
show a decrease in FRET ratio change the assay does not provide enough of a change to calculate a 
reliable dose response. This assay will have to be improved by either increasing cAMP levels or causing a 
greater difference in FRET ratio between the adenosine/SES and adenosine/PYY(3-36) samples. This can 
be done by modifying the assay in one or more of the following ways: optimizing receptor transfection, 
changing cell line, or changing the reporter.  
6.3.2 Determine half-life of 11 in vivo 
From chapter 4 I have shown that 11 has improved food intake reduction over Ex-4, but similar blood 
glucose control. One suspected reason for this is 11 has a longer half-life than Ex-4 causing appetite 
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suppressing effects to last longer. To test for this an ELISA will be used to test blood sample taken after 
administration of 11. These samples will be analyzed for total in vivo residency and be used to calculate a 
half-life for 11.  
6.3.3 Modify 11 to improve upon the pharmacokinetic properties 
Although 11 has improved weight loss capabilities when compared to Ex-4 it may be able to be 
further optimized. Additional sequence modifications to 11 could yield a more potent dual agonist or even 
triagonist. The in vivo effects of 11 are superior to Ex-4 and Ex-4/PYY(3-36) coadministration despite no 
evidence of NPY2R agonism and only slight agonism at the GIPR, when compared to native GIP. It is 
possible that GIPR agonism could be optimized through additional modifications. For this to be effective 
a binding study simulation between 11 and GIPR would need to be done.  
Addition of PYY(3-36) amino acid sequence could alter 11 enough to add NPY2R agonism. 14 has a 
significantly greater portion of PYY(3-36) and work at nanomolar concentration in vitro although showed 
no food intake reduction in vivo. Glucagon receptor agonism may also be added through an amino acid 
modification of E3Q.4  
6.3.4 Test 11 for pica and CTA response in rats 
11 is similar to Ex-4 in amino acid sequence and glucose control but more potent at appetite 
suppressing. If this enhanced appetite suppressing ability is due to an increase in brain uptake and 
increased receptor agonism of GLP-1R in the AN, an increase in nausea may play a role in weight loss. To 
test for an increase in nausea a pica and CTA test will be run on rats administered 11. 
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ABSTRACT: Peptide digestion from proteases is a
signiﬁcant limitation in peptide therapeutic development.
It has been hypothesized that the dietary pathway of
vitamin B12 (B12) may be exploited in this area, but an
open question is whether B12-peptide conjugates bound to
the B12 gastric uptake protein intrinsic factor (IF) can
provide any stability against proteases. Herein, we describe
a new conjugate of B12 with the incretin peptide exendin 4
that demonstrates picomolar agonism of the glugacon-like
peptide-1 receptor (GLP1-R). Stability studies reveal that
Ex-4 is digested by pancreatic proteases trypsin and
chymotrypsin and by the kidney endopeptidase meprin β.
Prebinding the B12 conjugate to IF, however, resulted in up
to a 4-fold greater activity of the B12-Ex-4 conjugate
relative to Ex-4, when the IF-B12-Ex-4 complex was
exposed to 22 μg/mL of trypsin, 2.3-fold greater activity
when exposed to 1.25 μg/mL of chymotrypsin, and there
was no decrease in function at up to 5 μg/mL of meprin β.
KEYWORDS: vitamin B12, exendin-4, intrinsic factor,
trypsin, AKAR3
■ INTRODUCTION
The human vitamin B12 (B12) dietary uptake pathway is a
complex process that facilitates access in humans to a vital
cofactor of methionine synthase and methyl malonyl CoA
mutase enzymes.1 This pathway involves three major binders,
two of which, intrinsic factor (IF) and haptocorrin (HC), being
critical for oral uptake (the third, transcobalamin II (TCII),
facilitates entry into cells upon enterocyte passage).2 HC
primarily protects B12 against acid digestion in the stomach and
is enzymatically digested upon entry of the HC-B12 complex
into the duodenum, whereupon the B12 is bound by IF. While
IF is produced in gastric parietal cells and can bind B12 in the
stomach, HC binding is preferred at the lower pH here and it is
only upon digestion of HC and a rise in pH in the intestine that
IF binding of B12 occurs naturally.
3,4 Concomitant with the rise
in pH is the release of pancreatic proteases, and it is critical to
note that IF, unlike HC, is resistant to pancreatic protease
digestion.5 IF is critical then for delivery of B12 through the
intestinal tract to the ileum where cubilin-amnionless based
receptor mediated enterocyte passage occurs.6 Employing this
pathway for oral peptide delivery, for example, requires
conjugation of the peptide to B12 in such a way that IF
recognition of B12 is not critically hindered and that B12
conjugated peptide can still exhibit the desired pharmacological
function. Such concerns are typically readily addressed,
however, and there are now several signiﬁcant examples of
B12-peptide conjugates that meet the above criteria.
7−11 What is
not understood, but is no less important, is whether such
peptide function is maintained when the conjugate is bound to
IF and whether IF, so eﬀective at protecting B12, can provide
any protection to a B12 conjugated peptide upon exposure to a
protease. To investigate these questions we decided to focus on
a highly potent peptide (Ex-4) that is the basis of a
pharmaceutical (exenatide) currently approved for treatment
of diabetes mellitus.12
Ex-4 was discovered in the venom of the Gila monster in
1992 by Eng et al. and is an incretin mimetic, sharing 53%
homology with glucagon-like peptide-1 (GLP-1). Like GLP-1,
Ex-4 stimulates the release of insulin through agonism of the
GLP-1 receptor (GLP-1R) (EC50 33 pM), eﬀectively lowering
blood glucose levels. Unlike GLP-1, Ex-4 is resistant to the
enzyme dipeptidyl peptidase IV (DPP-IV), which rapidly
cleaves and inactivates GLP-1 in vivo.13,14 Since DPP-IV
cleaves any peptide with an alanine or proline at the second
position from the N-terminus, substituting a glycine for the
alanine in GLP-1 results in the resistance seen in Ex-4. This
resistance allows Ex-4 to have a half-life of 2.4 h compared to
<2 min as seen for GLP-1.15 Such resistance to DPP-IV does
not, however, translate to other proteases, and exenatide
therefore must be administered subcutaneously.
The hypothesis herein then is that this pancreatic
degradation and general protease limitation may be overcome,
at least to some degree above unmodiﬁed peptide, by
conjugating B12 to Ex-4 and subsequently adding IF, assuming
the necessary maintenance of B12 binding by IF and Ex-4
agonism are controlled. To test these hypotheses we
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synthesized a B12-Ex-4 conjugate focusing on the lysine 12
(K12) position of Ex-4 and the ribose 5′-hydroxyl group of the
B12 moiety as sites of conjugation since both sites on the
respective moieties had published precedent for allowable
modiﬁcation.16−18 Binding to IF was conﬁrmed by radioassay,
and agonism of the GLP-1 receptor was then established for an
azido modiﬁed K12-Ex-4 (1), B12-Ex-4 (4), and IF-B12-Ex-4
(IF-4). With such establishing parameters controlled for
stability against the abundant intestinal endopeptidases, trypsin,
chymotrypsin, and the kidney protease meprin β19 were
compared for 1, 4, and IF-4.
■ EXPERIMENTAL SECTION
(AzidoK12)-Ex-4 (1) was conjugated to B12 at the K12 position
using Huisgens/Sharpless click chemistry,20 using Ex-4
modiﬁed at the lysine 12 ε-amine with an azido group during
solid-phase synthesis. The 5′ hydroxyl group of B12 was also
modiﬁed prior to coupling, being selectively oxidized to a
carboxylic acid (2) using 2-iodoxybenzoic acid, as previously
described by us.21 Subsequent coupling of 1-amino-3-butyne to
2 with 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide
(EDCI) and 1-hydroxybenzo-triazole (HOBt) produced B12
with a terminal alkyne at the ribose 5′-position (3) (see Scheme
1). Compound 3 was puriﬁed using a Shimadzu Prominence
HPLC on an Eclipse XDB C18 5 μm 4.6 mm × 150 mm
column with a mobile phase of 0.1% TFA water and elution
with acetonitrile on a gradient starting at 15% acetonitrile
increasing to 35% over 20 min (NMR for 3 is provided as
Supplementary Figure S1).
Compounds 1 and 3 were coupled using copper(II) sulfate
and sodium L-ascorbate (see Scheme 1). The new B12-Ex-4
conjugate (4) was puriﬁed with a Shimadzu HPLC using an
Eclipse XDB C18 5 μm 4.6 mm × 150 mm column with a
mobile phase of 0.1% TFA water and elution with acetonitrile.
A gradient run from 20% acetonitrile to 42% acetonitrile during
the ﬁrst 3 min and then 42 to 47.5% acetonitrile during the next
10 min was used to separate 4 from starting materials. The
product was conﬁrmed by matrix-assisted laser desorption/
ionization time of ﬂight mass spectrometer (MALDI-ToF MS)
(see Figure 1, inset). Compound 4 was puriﬁed to greater than
97% purity by HPLC (see Figure 1). The tendency of Ex-4 to
aggregate resulted in a small shoulder at 6.5 min.22
■ DISCUSSION
Initially, IF binding of 4 was conﬁrmed by radiometric chase
assay using 57Co-labeled B12 and compared to free B12, as
cyanocobalamin (see Figure 2).23 Signiﬁcant IF binding of 4
(6.8 nM) was maintained, albeit reduced from unmodiﬁed B12
(0.12 nM).
Once IF binding of 4 (IF-4) was conﬁrmed, agonism of the
GLP-1R was assayed for 1, 4, and IF-4 using HEK-293 cells
stably transfected with the GLP-1R (HEK-GLP-1R).25 To this
Scheme 1. Synthesis of B12-Ex-4 Conjugate 4
a
aReagents and conditions: (i) EDCI, HOBt, 1-amino-3-butyne, rt, 16 h; (ii) 1, CuSO4, sodium ascorbate, 1 h.
Figure 1. LC trace showing puriﬁed 4 as a monomer (∼7 min) and dimer (∼6.5 min) and MALDI-Tof MS (inset) of 4 showing m/z of 5658.153
Da, which corresponds to the +1 of 4.
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end, we employed a new assay that uses adenoviral transduction
to express the genetically encoded FRET reporter AKAR3 that
serves as a sensitive readout for cAMP production due to the
fact that AKAR3 undergoes a decrease of 485/535 nm emission
FRET ratio when it is phosphorylated by cAMP-dependent
protein kinase A (PKA) subsequent to GLP-1R activation.26−28
This is the ﬁrst instance to our knowledge of a FRET assay for
GLP-1R using viral AKAR3 and oﬀers a ready route to sensitive
high-throughput screening of the GLP-1R. An EC50 for 1, 4,
and IF-4 were measured at 26, 68, and 132 pM, respectively
(see Figure 3). It is worth noting that the azido modiﬁcation to
the K12 position of Ex-4 showed no signiﬁcant reduction in
potency compared to unmodiﬁed Ex-4 suggesting a useful
general route for selective conjugation to Ex-4 through click
chemistry approaches.20 Compounds 4 and IF-4 show that
further conjugation to the K12 position eﬀects function but still
demonstrates low picomolar eﬀective concentrations.
Compounds 1, 4, and IF-4 were analyzed for stability against
proteolysis by measuring remaining function at the receptor
compared to undigested controls. Compounds 1, 4, and IF-4
were tested for function at [100 nM], a concentration at which
each had comparable percent change in FRET ratio (see Table
1). Each protease was analyzed separately so that the protective
nature of B12 and IF could be analyzed for their eﬀect versus the
speciﬁc protease. The pH sensitivity of the assay prevented the
use of actual intestinal ﬂuids when testing the compounds.
Digestion was conducted in a standard extracellular solution
containing trypsin at 11, 22, or 50 μg/mL, chymotrypsin at
1.25, 3, or 6.25 μg/mL, or meprin β at 1 or 5 μg/mL (see
Figures 4 and S2).
At the lowest concentrations of trypsin (11 μg/mL) and
chymotrypsin (1.25 μg/mL) there is up to 50% greater function
for IF-4 relative to 4 alone with the highest concentration of
trypsin (50 μg/mL) and chymotrypsin (6.25 μg/mL) assayed
showing complete lack of function for all systems. The
digestion was monitored by measuring agonism of the drugs
at the GLP-1R, initially over the course of 3 h, although it was
quickly noted that there was no change after 1.5 h indicating
that the digestion had stopped by this time point (data not
shown). Subsequent triplicate runs were then performed on
digestions of 1.5 h.
Meprin β digestion revealed a 2-fold increase in function with
B12 conjugation and a 3-fold increase in function when
prebound to IF (see Figures 5 and S3). No function was
seen for 1 at concentrations greater than 3 μg/mL. The
protection provided from B12 conjugation and subsequent
binding to IF show that key residues are being protected.
Results of the AKAR3 assays show maintenance of function
where otherwise none was observed or improvement of
function when 4 is ﬁrst bound to IF.
■ CONCLUSIONS
The conservation or improved relative function demonstrated
herein for Ex-4 when conjugated to B12, and more signiﬁcantly
when bound by IF, is an important ﬁrst-step in addressing the
use and putative role of IF in protecting an administered
peptide (orally or by injected means). Protection against
pancreatic protease-catalyzed hydrolytic digestion of 4 was
maximal at a trypsin concentration of 22 μg/mL and 3 μg/mL
of chymotrypsin when 4 was prebound to IF, providing a 4-fold
and 5-fold positive increase in function, respectively, as
measured by GLP-1R agonism (utilizing the AKAR3 screening
assay). The digestion with metalloendoprotease meprin β
showed the most signiﬁcant protection when comparing 1 and
IF-4. No reduction in function was seen at the highest
concentration of meprin β tested (5 μg/mL), while 1 showed
no function at concentrations greater than 1 μg/mL of meprin
β. B12 provided some protection against trypsin relative to the
native peptide. The eﬀect is seen at 11 μg/mL of trypsin with a
relative 4-fold increase and at 1.25 and 3 μg/mL of
chymotrypsin with a relative increase of 3- and 5-fold. The
fact that the IF bound form IF-4 still maintained signiﬁcant
function at the GLP-1R is also highly signiﬁcant since many
routes to protect against intestinal degradation involve
encapsulation, which prevents possible luminal function or
absorption when in place. The use of IF to improve the
protease stability of a peptide oﬀers signiﬁcant scope for
exploitation. Even a small improvement in oral function, for
example, may be suﬃcient to achieve the desired eﬀect.
Combining this approach with a highly potent peptide with
known gut receptors that can produce a vagal aﬀerent response
(such as, but not limited to, GLP-1/Ex-4 or PYY3-36), for
example, may allow for a positive clinical outcome to be
achieved orally, without need even for systemic delivery.
Finally, as demonstrated by the stability against meprin β, there
is no suggestion that this approach is limited to oral use against
Figure 2. IF binding to B12 (0.12 nM) and 4 (6.8 nM). IF used in
these assays was produced in the plant Arabidopsis in the apo-form and
of high purity.24
Figure 3. Dose−response analysis of 1, 4, and IF-4 yielded EC50 values
of 26, 68, and 132 pM, respectively, as determined by monitoring the
485/535 nm FRET emission ratio.
Table 1. Percent Change in FRET at 100 nM for 1, 4, and
IF-4
compd % change in FRET at 100 nM
1 −12 ± 0.01
4 −13 ± 0.02
IF-4 −12 ± 0.01
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gastric proteases, but could also be expanded into serum
(through subcutaneous or intravenous injection of IF bound
B12-peptide conjugates, for instance), facilitating greatly
improved pharmacokinetics (especially when combined with
prior results showing B12 conjugation already improved sc
absorption of a PYY3-36 conjugate8), making this a possible
platform technology for peptide drug development.
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Rösmann, S.; Sterchi, E. E.; Stöcker, W. Differences in the Activation
Mechanism between the α and β Subunits of Human Meprin. Biol.
Chem. 2003, 384, 825−83.
Molecular Pharmaceutics Communication
DOI: 10.1021/acs.molpharmaceut.5b00390
Mol. Pharmaceutics 2015, 12, 3502−3506
3506
89
Solution Structure and Constrained Molecular Dynamics
Study of Vitamin B12 Conjugates of the Anorectic Peptide
PYY(3–36)
Kelly E. Henry,[a] Deborah J. Kerwood,[a] Damian G. Allis,[a] Jayme L. Workinger,[a]
Ron L. Bonaccorso,[a] George G. Holz,[b] Christian L. Roth,[c] Jon Zubieta,[a] and
Robert P. Doyle*[a, b]
Introduction
Peptide YY (PYY), a member of the pancreatic polypeptide
family,[1–8] was first isolated from porcine intestinal tissue ex-
tracts in 1980[9] and was later shown to be a critical enteroen-
docrine hormone involved in appetite regulation.[10–12] PYY has
two main circulating forms: PYY(1–36) and a truncated form,
PYY(3–36).[13] PYY(1–36) is released in concert with caloric
intake or exercise and is cleaved by dipeptidyl peptidase IV
(DPP-IV)[14] in the gut to produce PYY(3–36). PYY(1–36) has an
appetite-stimulating effect through activation of the orexigenic
Y1 receptor (Y1-R) located in the intestines, blood vessels, and
brain.[15] The two-amino-acid N-terminal (Tyr-Pro) truncation to
PYY(3–36) results in an approximate 100-fold decrease in activi-
ty at the Y1-R,[5, 16] and generates an agonist of the anorexigen-
ic Y2 receptor (Y2-R) located in the intestines (vagal afferent
sensory neuron signaling)[17,18] and brain,[19,20] which exerts a G-
protein-coupled receptor (GPCR) Gi-mediated anorectic effect.
We recently reported a B12–PYY(3–36) conjugate that dem-
onstrated similar activity to native PYY(3–36) at the Y2-R in vi-
tro, but improved function over PYY(3–36) upon subcutaneous
(s.c.) administration in vivo in a lean rat model (conjugate 3 as
described herein below).[21] In earlier work, we focused on con-
jugating to B12 through the ribose hydroxy group, as it is well
established in the field that this is an optimal site for such con-
jugation, as it does not hinder recognition of B12 by its carrier
proteins.[22–25] Likewise, we focused on an N-terminal region of
PYY(3–36) for conjugation (specifically the K4 residue), because
again it has been well documented that modifications at (or
indeed complete loss of) this area do not significantly affect
Y2-R agonism.[26–28] These assumptions bore out, as the EC50
values at the Y2-R obtained for the conjugate produced (and
noted as conjugate 3 herein) were similar to that of unconju-
gated PYY(3–36) used for comparison. These were established
using a Fura-2 assay that monitors intracellular Ca2+ mobiliza-
tion under conditions in which the Y2-R signals through a pro-
miscuous Gq GTP binding protein.
[21] Questions that remained
from this work, however, were what affect, if any, does B12 con-
jugation actually have on the PYY(3–36) secondary structure
and whether MD simulations could be used to better under-
stand, and possibly predict, any structural modifications ob-
served. To investigate these questions, two conjugates located
at the same coupling sites (ribose on B12 and K4 on PYY(3–36)
Vitamin B12–peptide conjugates have considerable therapeutic
potential through improved pharmacokinetic and/or pharma-
codynamic properties imparted on the peptide upon covalent
attachment to vitamin B12 (B12). There remains a lack of struc-
tural studies investigating the effects of B12 conjugation on
peptide secondary structure. Determining the solution struc-
ture of a B12–peptide conjugate or conjugates and measuring
functions of the conjugate(s) at the target peptide receptor
may offer considerable insight concerning the future design of
fully optimized conjugates. This methodology is especially
useful in tandem with constrained molecular dynamics (MD)
studies, such that predictions may be made about conjugates
not yet synthesized. Focusing on two B12 conjugates of the
anorectic peptide PYY(3–36), one of which was previously
demonstrated to have improved food intake reduction com-
pared with PYY(3–36), we performed NMR structural analyses
and used the information to conduct MD simulations. The
study provides rare structural insight into vitamin B12 conju-
gates and validates the fact that B12 can be conjugated to
a peptide without markedly affecting peptide secondary struc-
ture.
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but with a slightly varying spacer length (one methylene unit
difference) were assayed for agonism of the Y2-R using a new
fluorescence resonance energy transfer (FRET)-based assay that
faithfully reports the normal signal transduction process by
which the Y2-R signals through Gi proteins to lower levels of
intracellular cyclic adenosine monophosphate (cAMP).[29] NMR
structures were solved for these conjugates, and their in-solu-
tion NMR structures were compared with those previously re-
ported by Keire et al.[30] and Nygaard et al.[7] Subsequent un-
constrained and NMR constrained MD simulations were then
also performed.
Results and Discussion
In vitro evaluation of conjugates 3 and 4
All assays were performed at least in triplicate. Conjugates 3
and 4 were tested for their abilities to lower cAMP levels.
Figure 1 shows the dose–response relationships for 3 and 4
relative to K4PYY, showing both conjugates are less active than
K4PYY and that 4 is more active than 3. Both conjugates are,
however, within one-half log order of K4PYY.
This difference in EC50 values in comparing conjugates with
K4PYY was initially presumed to be a compromise between
steric hindrance and/or unfavorable flexibility resulting in
modifications/interactions that negatively affect the peptide
structure–activity profile. At this point we decided to pursue
NMR and molecular dynamics (MD) studies to further explore
these in vitro observations.
NMR analysis of 3 and 4
Proton chemical shifts for 3 were assigned by analyzing TOCSY,
DQF-COSY, and 2D NOE spectra at 25 8C. The experiments were
also performed at 20 and 30 8C, at which slight shifts of some
proton signals resolved overlapping peaks. The NMR spectra of
3 have some similarity to those of PYY(3–36), such as line
broadening of many signals,[7] indicating increased dynamics,
and a decrease in the chemical shift range of the backbone
amide protons relative to full-length PYY. All backbone amide
protons were assigned with the exception of Leu24, which
could not be definitely determined due to overlap. Figure S17
(Supporting Information) shows the proton chemical shift dif-
ference between 3 and PYY(3–36). There are chemical shift dif-
ferences for residue Lys4, which is not surprising, as this is the
attachment site for B12. Figure 2 shows an overlay of 3 after
MD calculations and PYY(3–36). The first chemical shift differ-
ence to consider is that for the methyl and a protons of Ala7.
In PYY(3–36), the methyl group of residue Ala7 is pointing
toward the a helix, whereas in conjugate 3 the methyl group
is oriented away from the a helix. A 2D NOE cross-peak be-
tween the Ala7 methyl group and the ring protons of Tyr20
was observed in PYY(3–36),[7] but in 3 only a very weak cross-
peak was observed in the longest mixing time 2D NOE experi-
ment. This difference in orientation would also put the Ala7
a proton in distinct environments. The backbone amide pro-
tons have different chemical shifts for the b turn residues and
residues in the N-terminal side of the a helix, specifically resi-
dues Gly9, Ala12, Ser13, Glu15, Leu17, and Arg19. This can be
explained by the unraveling of the a helix and increased dy-
namics at the N-terminal side in the PYY(3–36) structure. Con-
jugate 3 maintains an a-helical structure similar to that of full-
length PYY, and the residue with the largest chemical shift dif-
ference for the amide proton, Leu17, has a chemical shift value
closer to that of the full-length peptide: PYY Leu17 NH
8.40 ppm,[7] 3 Leu17 NH 8.36 ppm, PYY(3–36) 7.95 ppm.[7] Ny-
gaard et al. suggest that the Pro2–Tyr27 interaction is impor-
tant for the stability of the PP fold, and that loss of this interac-
tion in PYY(3–36) creates both conformational and dynamic
changes in the structure, especially around the turn region.[7]
Close inspection of 3 indicates possible hydrogen bonds from
Glu6 to Tyr27 and Ser23, which may stabilize the PP fold in the
conjugate.[7]
Figure 1. Dose–response curves monitored as percent inhibition of Ex-4
action at AKAR3 by K4PYY and conjugates 3 and 4 at the Y2-R. EC50 values:
K4PYY: 10.2 nm, 3 : 62 nm, 4 : 20.2 nm. EC50 values are the average
SEM.
Figure 2. Overlay of PYY(3–36) (blue) versus 3 (tan). The structure of PYY(3–
36) was obtained from the RCSB Protein Data Bank (www.pdb.org); PDB ID:
2DF0. The program Chimera (UCSF; www.cgl.ucsf.edu/chimera/)[31] was used
to display the image.
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To elaborate on the structural studies, we decided to also in-
vestigate the solution structure of 4 to allow a direct compari-
son with 3. Based on the NMR spectra, the conjugate struc-
tures appear very similar with only minor differences in the
proton chemical shift assignments (Supporting Information
Figure S18) and greater than 95% similarity in the 2D NOE
spectra (Supporting Information Figure S19).
The major difference observed between 3 and 4 is the
proton chemical shift change at B7 and B2 on the dimethyl-
benzimidazole (DMB) ligand (see Supporting Information Fig-
ure S12 for B12 atom numbering scheme). The C20 methyl pro-
tons are closer to the B4 and B2 protons in 4 based on the
presence of a weak cross-peak between the C20 methyl pro-
tons and B2, which is only seen in the longest mixing time 2D
NOE spectra of 3, and a cross-peak between the methyl pro-
tons and B4, which is stronger for 4. Weak cross-peaks are ob-
served in 4 between a propionamide proton of the g side
chain of B12 (Supporting Information Figure S12) and the Ha of
D11 as well as the methyl protons of A12. The a helix motif as
a whole is critical for association and subsequent agonism.[26]
This is consistent with reported Y2-R interactions, as the C-ter-
minal pentapeptide region is well established as the critical
region, or “address”, of the main interactions with Y2-R, while
the a helix is considered the “message”, indicating that both
areas are critical in Y2-R agonism.[26]
NMR constrained MD studies of 3 and 4
Molecular dynamics simulations of 3 and 4 were performed
both with and without the NMR constraints defined for 3 to
consider differences in behavior and potential alternative struc-
tures in the simulations. The observed structural changes
across the simulations identified intra-PYY(3–36) interactions
that might, through their stabilization in the isolated conju-
gate, promote the decreased activity of 3 relative to 4. The un-
constrained MD simulation data then provide an additional set
of structures for considering accessible geometries beyond the
restrained set. The average structures from representative MD
time ranges for 3 and 4 are shown in Figures 3 (front/side
view) and 4 (top view). Apparent from these views, and the
full simulations in general, are the persistence of 1) much of
the a helical structure and 2) localization of the B12 fragment
itself to the unstructured region approaching the loop into the
a helix (in the images, this loop is at the base of all structures,
including residues Glu10, Asp11, and Ala12). Across all of the
simulations, several hydrogen bonding motifs are found to
persist at the onset of the simulations and over the time evolu-
tion of the structure dynamics that serve to effectively anchor
the B12 at this loop region. Those which specifically anchor the
B12 to this region in all simulations are shown in Figure 5, visu-
alizing the two most persistent motifs for these structures :
a pair of hydrogen bonds from a single B12 amide side chain to
Pro8 and Glu16 (left, Motif 1) and an amide side chain to Pro8
hydrogen bond and coordination of a hydroxy group H atom
on Ser13 to the B12 cyano nitrogen atom (right, Motif 2). The
structural basis for preservation of the loop region itself across
all simulations is evident in Figure 6, which shows that (left)
Glu16 is engaged in several persistent hydrogen bonding inter-
actions with Gly9, Glu10, and Asp11, whereas at the far end of
the loop (right), Glu6 is in close proximity to hydrogen bond
acceptors on Tyr27 and Ser23. The NMR distance lists, ranges,
and time-averaged MD structures for 3 and 4 are provided in
the Supporting Information.
Figure 3. Side-on views (aligned along the a helix) of RMSD average structures (across 10 ns sampling increments) for restrained (left) and unrestrained (right)
MD simulations of A) 3 and B) 4.
ChemMedChem 2016, 11, 1015 – 1021 www.chemmedchem.org Ó 2016 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim1017
Full Papers
92
The differences between structures 3 and 4, both with and
without NMR constraints, are largely localized to the C-terminal
side of the a helix and occur to varying degrees in all of the
simulations. With the B12 largely predicted to be confined to
the PYY(3–36) loop due to several strong hydrogen bonding
interactions, and with the well-known attenuation of PYY(3–
36) activity with modifications to or removal of the C-terminal
region, the most logical explanation for any change in behav-
ior to come from these single conjugate simulations is some
structural change at the C-terminal region of PYY(3–36). This
may occur from B12 binding-induced conformational changes
at the PYY N terminus, causing changes in activity, meaning
any observed interactions between the B12 binding-constrained
N terminus and concomitantly proximal C-terminal regions are
of great interest. Despite the small change in tether length for
these two cases, RMSD analyses and average structure genera-
tion produced two distinct structures that, for each case, re-
vealed binding interactions deemed consistent with the trends
in activity.
MD simulations of 3 and 4 highlight hydrogen bonding in-
teractions that may govern the differences observed in Y2-R
agonism and subsequent calcium mobilization and inhibitory
cAMP effects. PYY(3–36) does not tolerate any interaction at
the C terminus with respect to Y2-R stimulation.[32] If the
Figure 4. Top-down views (aligned along the a helix) of RMSD average structures (across 10 ns sampling increments) for restrained (left) and unrestrained
(right) MD simulations of A) 3 and B) 4.
Figure 5. Two persistent hydrogen bonding interaction motifs between the B12 and PYY(3–36) unstructured region (residues 3–10) across all simulations.
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answer to the decreased activity of 3 lies solely on some re-
sponse internal to the conjugate, one might argue from the
MD simulations that the shortened tether length enhances the
stiffness of the unstructured region (residues 3–9) by decreas-
ing its conformational flexibility upon hydrogen bonding be-
tween the B12 and the near-loop region. This result would pro-
vide a less flexible N-terminal region and a more persistent hy-
drogen bonding pocket for the C-terminal region with which
to interact. By the loss of flexibility, necessary at the C-terminal
region for biological activity, reduced activity would be predict-
ed (and is observed). Kaiser et al. recently reported data show-
ing that unwinding of C-terminal residues of neuropeptide Y
(NPY) is critical for Y2 receptor binding and activation.[32] Solu-
tion NMR experiments showed that the ligand is tethered to
the second extracellular loop by hydrophobic contacts and re-
vealed NPY to undergo remarkable structural changes within
the C terminus. The C-terminal pentapeptide plays a role in ex-
tensive and susceptible interactions in NPY; a network that is
also relevant for PYY(3–36) in regards to Y2-R agonism.
Changes in the C-terminal amino acids can easily disturb re-
ceptor binding or switch receptor selectivity for both NPY and
PYY(3–36) as observed in numerous earlier structure-activity
studies.[33] The ultimate conclusion from Kaiser et al. directly re-
lates to our work, as the binding mode of NPY [and in our
case, B12 conjugates of PYY(3–36)] might have more general
implications for peptide binding GPCR systems.
The MD simulations from this study do indicate that if the
origin of the decreased activity of 3 is entirely due to factors
internal to the B12–PYY(3–36) conjugate itself, then constraint
of the C-terminal region by hydrogen bonding interactions
with the N-terminal region could explain it—and that this kind
of internal mechanism may have its origin in the reduction of
tether length.
Conclusions
B12–PYY(3–36) conjugates 3 and 4 with various methylene
spacer lengths between the B12 and PYY(3–36) show similar
Y2-R agonism to that of PYY(3–36). Both intra- and intermolec-
ular interactions between B12 and the peptide and small
changes in the secondary structure of the peptide brought on
by conjugation were observed. Based on the information col-
lected from the NMR constrained MD studies, it would have
been possible to offer a detailed assessment of the potential
function of both conjugates. These observations suggest that
MD could be used a priori to guide conjugate rational design
and minimize the number of conjugates that would need to
be screened—information of considerable benefit in develop-
ment terms. Conjugates and modifications of B12 have gar-
nered much interest in recent years for their clinical and me-
dicinal applicability.[34] Based on the studies described herein,
an ideal B12–peptide conjugate would be one with an appro-
priate linker length to allow optimal function of both the pep-
tide and B12, which could be predicted by MD via inter- and in-
tramolecular interactions that are known to be useful and/or
harmful to the overall function of each component.
Experimental Section
Synthesis of alkyne precursors (1 and 2) and conjugates (3 and
4): Two B12–alkyne precursors were prepared by activation of a B12–
carboxylic acid (B12-CA) derivative
[35] with 1-ethyl-3-(3-dimethylami-
nopropyl)carbodiimide (EDC) and hydroxybenzotriazole (HOBt) in
anhydrous DMSO under argon (Scheme 1). Full characterization of
the alkyne precursor 1 and 2, including RP-HPLC, MALDI-ToF MS,
and NMR can be found in the Supporting Information (Figure S1–
11, Table S1). For conjugate synthesis, click chemistry[36] was imple-
mented using a copper iodide (CuI) and tris[(1-benzyl-1H-1,2,3-tria-
zol-4-yl)methyl]amine (TBTA) method, adapted from Gryko
et al.[37,38] Copper(I)-catalyzed alkyne–azide cycloaddition (CuAAC)
synthesis of conjugates 3 and 4 via the alkyne precursors 1 and 2
and a K4-azido PYY(3–36) (K4PYY) is described in Scheme 2 (spacer
length n=2, 3 for precursors 1 and 2). K4PYY was initially tested
against PYY(3–36) amide (Sigma–Aldrich), and there was no ob-
served difference in Y2-R agonism. Subsequently, K4PYY was used
as the control for all assays. Characterization of the B12-PYY(3–36)
conjugates 3 and 4, including HPLC and MALDI-ToF MS, can be
found in the Supporting Information (Figure S13–16).
Figure 6. Two persistent hydrogen bonding motifs that define the PYY(3–36) loop region (left) and stabilizing interactions between the unstructured N-termi-
nal region and the a helix.
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In vitro assay of 3 and 4 at the Y2 receptor coupled to Gi : Conju-
gates 3 and 4 were tested for their abilities to lower levels of
cAMP in an in vitro assay using HEK293 cell monolayers
(Figure 7).[29] These cells were engineered so that they stably ex-
press the human GLP-1 receptor (GLP-1R), while also transiently ex-
pressing the human Y2-R. Furthermore, these cells were virally
transduced with the genetically encoded FRET reporter AKAR3,
which is used to monitor cAMP-dependent protein kinase (PKA) ac-
tivation intracellularly. This assay is unique in that it allows FRET-
based detection of the ability of PYY(3–36) to counteract the
action of a GLP-1R agonist (Exendin-4; Ex-4) to raise levels of cAMP.
When the cells are first treated with Ex-4 (33 pm ; injection 1) so
that levels of cAMP are elevated, AKAR3 exhibits increased FRET,
measured as a decrease in the 485/535 nm emission ratio
(Figure 7). This change of FRET occurs after an approximate lag
time of 50 s. If PYY(3–36) is then applied at the 180 s time point
(injection 2), a functional antagonism of the action of Ex-4 is mea-
sured so that the change of FRET is decreased. Note that no
change of FRET is measured in response to the adminis-
tration of a negative control standard extracellular saline
(SES; Figure 7). By varying the concentration of added
conjugate, it is possible to determine dose–response re-
lationships, and to also determine EC50 values describing
inhibitory actions of PYY(3–36) conjugates versus 33 pm
Ex-4 in this assay. Figure 7 illustrates these responses to
the first injection of either Ex-4 or SES, and the second
injection of K4PYY or SES. To normalize these raw data
for subsequent dose–response analysis, “end-point”
values of FRET were measured during the last 10 sample
intervals (Figure 7). As illustrated in Figure 1, the dose-
dependent inhibitory actions of PYY(3–36) conjugates
are then quantified relative to a value of 100% that cor-
responds to the maximal inhibitory effect measured
when testing 300 nm PYY(3–36) in this assay.
NMR studies of 3 and 4 : NMR studies were executed ini-
tially to observe any structural differences between the
conjugates and free peptide in solution. Because in vivo
studies had previously established in vivo function for 3,
extensive structural studies were first performed with 3
and a direct comparison made to published PYY(3–36).[7]
Full NMR studies of 4 were then completed to serve as
Scheme 1. Synthesis of B12–alkyne precursors 1 and 2. Reagents and conditions : EDC, HOBt, anhydrous DMSO; reactions carried out under argon for 16 h at
RT.
Scheme 2. Copper(I) alkyne–azide cycloaddition synthesis of B12–PYY(3–36) conjugates 3
and 4 via alkyne precursors 1 and 2 with a two- or three-methylene-unit spacer between
the 5’-amide on B12 and the triazole linkage to K4PYY. Reagents and conditions : Cu
I, TBTA;
reactions were carried out for 16 h at RT. PYY(3–36) adapted from PDB ID: 2DF0.
Figure 7. D485/535 FRET ratio through the course of a run. The first injection
occurs at 100 s followed by a second injection at 180 s.
ChemMedChem 2016, 11, 1015 – 1021 www.chemmedchem.org Ó 2016 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim1020
Full Papers
95
a comparison with 3. Full descriptions of methods and conditions
are provided in the Supporting Information.
MD studies of 3 and 4 : To complement the NMR studies, MD sim-
ulations of 3 and 4 were completed in attempts to explain the
minor differences of Y2-R agonism between the two conjugates.
These MD studies took the form of 50 ns simulations to probe the
potential variation in simulation geometries and time-averaged
structures that arise from different tether lengths. MD simulations
were performed using the GROMACS (ver. 5.0.4)[39] software pack-
age. The NMR distance lists, ranges, and tabulated distances from
the time-averaged MD structure for 3 are provided in the Support-
ing Information.
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TITLE 
COAGONISTS OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR 
AND NEUROPEPTIDE Y2 RECEPTOR 
BACKGROUND OF THE INVENTION 
1. FIELD OF THE INVENTION
[0001] The present invention relates to peptides for treating weight loss and glucose 
levels and, more specifically, to a single peptide that can trigger weight loss while controlling 
glucose levels.   
2. DESCRIPTION OF THE RELATED ART
[0002] The glucagon-like peptide 1 receptor (GLP-1R) is involved in stimulating the 
release of insulin in a glucose dependent manner.  As a result, GLP-1R agonists have been the 
source of development for drugs that can be used to treat insulin deficiency diseases such as 
diabetes.  The neuropeptide Y2 receptor (NPYR2) is involved in appetite signaling and 
suppression.  Accordingly, there is a need in the art for a drug that could serve as an agonist of 
both receptors, thereby more fully addressing the problems associated with glucose regulation 
and food intake.   
[0003] BRIEF SUMMARY OF THE INVENTION 
[0004] The present invention comprises peptide sequences that can serve as agonists of 
both the glucagon-like peptide 1 receptor (GLP-1R) and the neuropeptide Y2 receptor (NPYR2).  
In particular, the invention comprises certain non-naturally occurring peptides that can 
successfully serve as agonists for both receptors.  The present invention may also be used as a 
coagonist at other receptors, such as the NPYR1 or NPYR4 or NPYR5, and not necessarily 
exclusively GLP-1R and NPYR2. 
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BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S) 
[0005] The present invention will be more fully understood and appreciated by reading 
the following Detailed Description in conjunction with the accompanying drawings, in which: 
[0006] FIGS. 1A and 1B are graphs of the results of agonism screening for certain 
peptides according to the present invention; 
[0007] FIGS. 2A and 2B are graphs of the results of agonism screening for certain 
peptides according to the present invention; 
[0008] Fig. 3 is a chart of GLP-1R agonism screening for certain peptides at a 
concentration of 100nM; 
[0009] Fig. 4 is a chart of NPYR2 agonism screening for certain peptides at a 
concentration of 100nM; 
[0010] Fig. 5 is a graph of GLP-1R agonism of an exemplary peptide according to the 
present invention; 
[0011] Fig. 6 is a graph of NPYR2 agonism of an exemplary peptide according to the 
present invention; 
[0012] Fig. 7 shows the comparison of Ex-4 and PYY and highlights the critical 
components of each; and 
[0013] Fig. 8 shows potential variations of RLB001 that may have comparable or better 
function at both the GLP-1R and NPYR2. 
DETAILED DESCRIPTION OF THE INVENTION 
[0014] Referring now to the drawings, wherein like reference numerals refer to like parts 
throughout, the present inventions comprises peptide sequences that are coagonists of GLP-1R 
and NPYR2.  The sequences of the present invention were designed by combining certain 
98
aspects of the natural substrates or known agonists of GLP-1R and NPYR2., such as Peptide YY 
and exendin-4. 
[0015] Following the approach of the present invention, the sequences 
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSTRQRY-NH2 (SEQ. ID NO. 1), referred to 
herein as Peptide RLB001, HGEGTFTSDLSKQMEEEAVRLFIEWLRHYLNLVTRQRY-NH2 
(SEQ. ID NO. 2), referred to herein as Peptide RLB002, and 
IKPEAPREDASPEEENQAYKEFIAYLNLVTRQRY-NH2 (SEQ. ID. NO. 3), referred to herein 
as Peptide RLB003 were designed and synthesized through solid phase peptide synthesis.   
[0016] Referring to FIGS. 1A and 1B, the sequences were screened for agonism with 
respect to each of GLP-1R and NPYR2 by performing a either a Fluorescence Resonance Energy 
Transfer (FRET) assay to show GLP-1R agonism or following the fluorescence of FURA 2 upon 
calcium release to show NPYR2 agonism and plotting the change in either FRET or fluorescence 
over a predetermined time period. These assays have been used previously to show function at 
each receptor respectively.  The peptides synthesized according to the present invention were 
compared against a basal measurement, exendin-4 (a known agonist of GLP-1R), Peptide YY (a 
known agonist of NPYR2), and ionomycin.   
[0017] Referring to FIGS. 2A and 2B, Peptide RLB001 was screened for agonism with 
respect to each of GLP-1R and NPYR2, as well as the controls discussed above.  Referring to 
FIG. 3, screening of the peptides for GLP-1R agonism revealed that RLB001 and RLB002 were 
effective agonists.  Referring to FIG. 4, screening of the peptides for NPYR2 agonism revealed 
that RLB001 was even more effective that known agonists of NPY2R, such as PYY.  As seen in 
FIG. 5, Peptide RLB001 done in triplicate has an EC50 of 50 pM at GLP-1R.  As seen in FIG. 6, 
Peptide RLB001 done in duplicate has an EC50 of 81 nM at NPYR2.  The relevant portions of 
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PYY and exendin-4 used as a basis for forming the sequences according to the present invention 
are seen in FIG. 7.  Referring to FIG. 8, SEQ ID NO. 4 through SEQ ID NO. 12 represent 
variations of RLB001 that may have comparable or better function at both the GLP-1R and 
NPYR2 and may be readily tested as described above to confirm their efficacy.  The present 
invention may also be used as a coagonist at other receptors, such as the NPYR1 or NPYR4 or 
NPYR5, and not necessarily exclusively GLP-1R and NPYR2 
[0018] These results demonstrate that the peptide RLB001 has comparable function at 
the GLP-1R and the NPYR2.  A single peptide may thus be used to activate two receptors 
responsible for glucose control and appetite suppression.  In addition, the unique profile of 
calcium release after activation at the NPYR2 may indicate biased agonism.  
[0019] Sequences according to the present invention may be further modified according 
to known processes, such as glycosylation, to improve the use of the sequences as 
pharmaceuticals by assisting with the delivery of the protein to a subject.  For example, N-linked 
glycosylation may be used to attach oligosaccharides to a nitrogen atom, such as the N4 of 
asparagine residues.  Similarly, O-linked glycosylation may be used to attach glycans to serine 
and threonine and C-linked glycosylation used for the covalent attachment of a mannose residue 
to a tryptophan residue. 
[0020] Sequences according to the present invention may be further modified by 
pegylation, which is the attachment of a therapeutic protein to poly(ethylene glycol) polymer 
chains (PEG).  The attachment of poly(ethylene glycol) chains can prevent degradation by 
proteolytic enzymes, reduce rapid clearance of the sequences by the kidneys, and increase the 
circulating half-life.  As is known in the art, PEG is linked to a protein sequence through reactive 
molecular groups on amino acid side chains such as lysine. 
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[0021] Sequences according to the present invention may be further modified by 
lipidation.  The presence of a lipid group in peptides modulates their hydrophobicity, secondary 
structures and self-assembling propensities while retaining their abilities to bind to target 
receptors. Lipidation improves metabolic stability, membrane permeability, bioavailability, and 
changes pharmacokinetic and pharmacodynamic properties of peptides.   
[0022] The sequences may also be encapsulated in a suitable vehicle to either aid in the 
delivery of the compound to target cells, to increase the stability of the composition, or to 
minimize potential toxicity of the composition. For example, nanoparticles, liposomes, 
microemulsions, micelles, dendrimers and other phospholipid-containing systems may be used as 
is known in the art. 
[0023] Sequences according to the present invention may further be conjugated to known 
conjugation partners to assist in the use of the sequences as a pharmaceutical. For example, 
conjugation partners such as an organic drug molecule, an enzyme label, a toxin, a cytostatic 
agent, a label which can be photoactivated and which is suitable in photodynamic therapy, a 
pharmaceutically suitable radioactive label, a hapten, digoxigenin, biotin, a chemotherapeutic 
metal complex or metal, colloidal gold, or a moiety that extends the serum half-life may be used 
to assist with the delivery of the present invention.  
[0024] The present invention includes pharmaceutical compositions comprising a 
preparation of the sequences of the invention. Such pharmaceutical compositions may be for 
administration for injection, or for oral, nasal, transdermal or other forms of administration, 
including, e.g., by intravenous, intradermal, intramuscular, intramammary, intraperitoneal, 
intrathecal, intraocular, retrobulbar, intrapulmonary (e.g., aerosolized drugs) or subcutaneous 
injection (including depot administration for long term release); by sublingual, anal, vaginal, or 
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by surgical implantation.  The treatment may consist of a single dose or a plurality of doses over 
a period of time.  In general, pharmaceutical compositions comprising effective amounts of a 
sequence according to the invention, whether modified as described above or not, together with 
pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or 
carriers. Such compositions include diluents of various buffer content, pH and ionic strength; 
additives such as detergents and solubilizing agents, anti-oxidants, preservatives and bulking 
substances.  The pharmaceutical compositions optionally may include still other 
pharmaceutically acceptable liquid, semisolid, or solid diluents that serve as pharmaceutical 
vehicles, excipients, or media.  Such compositions may influence the physical state, stability, rate 
of in vivo release, and rate of in vivo clearance of the present proteins and derivatives. The 
compositions may be prepared in liquid form, or may be in dried powder, such as lyophilized 
form.  Implantable sustained release formulations are also contemplated, as are transdermal 
formulations. 
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WHAT IS CLAIMED IS: 
1. A composition for simultaneously treating obesity and insulin deficiency,
comprising a peptide sequence having a first portion that corresponds to a selected portion of the 
sequence of an agonist of the glucagon-like peptide 1 receptor (GLP-1R) and a second potion 
that corresponds to a selected portion of the sequence of an agonist of the neuropeptide Y2 
receptor (NPYR2). 
2. The composition of claim 1, wherein the sequence comprises
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSTRQRY-NH2 (SEQ. ID NO. 1). 
3. A method of simultaneously treating obesity and insulin deficiency, comprising
the steps of administering a peptide sequence having a first portion that corresponds to a selected 
portion of the sequence of an agonist of the glucagon-like peptide 1 receptor (GLP-1R) and a 
second potion that corresponds to a selected portion of the sequence of an agonist of the 
neuropeptide Y2 receptor (NPYR2). 
4. The method of claim 1, wherein the sequence comprises
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSTRQRY-NH2 (SEQ. ID NO. 1). 
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ABSTRACT 
Peptide sequences that can serve as agonists of both the glucagon-like peptide 1 receptor 
(GLP-1R) and the neuropeptide Y2 receptor (NPYR2).  The peptide sequences include regions 
that correspond to certain aspect of natural substrates and known agonists of the glucagon-like 
peptide 1 receptor (GLP-1R) and the neuropeptide Y2 receptor (NPYR2) in a single sequence.
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 FIGS. 1A and 1B 
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FIGS. 2A and 2B 
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FIG. 5 
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Ex-4 
 
 
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2   
 
PYY 
 
 
IKPEAPREDASPEELNRYYASLRHYLNLVTRQRY-NH2 
 
RLB001 
 
 
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSTRQRY-NH2 
 
RLB002 
 
 
HGEGTFTSDLSKQMEEEAVRLFIEWLRHYLNLVTRQRY-NH2 
 
RLB003 
 
 
IKPEAPREDASPEEENQAYKEFIAYLNLVTRQRY-NH2 
 
FIG. 7  
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 1 HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGTRQRY-NH2 (SEQ. ID. NO. 4) 
2 HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGTRQRY-NH2 (SEQ. ID. NO. 5) 
3 HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGLRHYLNLVTRQRY-NH2 (SEQ. ID. NO. 6) 
4 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRGTRQRY-NH2 (SEQ. ID. NO. 7) 
5 HGEGTFTSDVSSYLEGQAAKEFIAWLVKGRGTRQRY-NH2 (SEQ. ID. NO. 8) 
6 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRGLRHYLNLVTRQRY-NH2 (SEQ. ID. NO. 9) 
7 HGEGTFTSDVSSYLEGQAAKEFIAWLVKGRGLRHYLNLVTRQRY-NH2 (SEQ. ID. NO. 10) 
8 HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSTRQRY-NH2 (SEQ. ID. NO. 11) 
9 HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSLRHYLNLVTRQRY-NH2 (SEQ. ID. 
NO. 12)     
Fig. 8 
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